JPN
ENG

The 88th Annual Scientific Meeting of the Japanese Circulation Society

Program

Time Table

★: English Session    ◆: Partially English

March 8 (Fri.) [PDF]

March 9(Sat.) [PDF]

March 10(Sun.) [PDF]

Mikamo Lecture（Sponsored by Japan Heart Foundation）

Stem Cells & Genomics: From Cardiovascular Precision Medicine to Clinical Trial in Dish

March 9 (Sat), 2024 10:30-11:30 Room 1 Kobe Portopia Hotel 1F Portopia Hall

English

Chairpersons: Issei Komuro Department of Frontier Cardiovascular Science,
The University of Tokyo/International University of Health and Welfare, Tokyo
Speaker: Joseph C. Wu Stanford University School of Medicine, USA

Mashimo Memorial Lecture

Whole Genome Project for Medial Implementation and Future Vision~ From the Perspective of Cancer Genomic Medicine in Japan ~

March 8 (Fri), 2024 14:10-15:00 Room 1 Kobe Portopia Hotel 1F Portopia Hall

Japanese

Chairpersons: Kinya Otsu National Cerebral and Cardiovascular Center, Suita
Speaker: Hitoshi Nakagama National Cancer Center, Tokyo

President's Lecture

Japanese

Mission and vision of our JCS

March 9 (Sat), 2024 13:30-14:00 Room 1 Kobe Portopia Hotel 1F Portopia Hall

PA
Chairpersons: Yoshihiko Saito COE, Nara Prefecture Seiwa Medical Center, Sango
Speaker: Ken-ichi Hirata Department of Internal Medicine, Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe

Congress Chairperson's Lecture

Japanese

Challenging the Prevention of Atherosclerosis

March 8 (Fri), 2024 13:30-14:10 Room 1 Kobe Portopia Hotel 1F Portopia Hall

CL
Chairpersons: Toru Kita President, Kobe City College of Nursing, Kobe
Speaker: Ken-ichi Hirata Department of Internal Medicine, Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe

Plenary Session

English

Plenary Session 1

March 8 (Fri), 2024 08:00-09:30 Room 2 Kobe Portopia Hotel South Building 1F Ohwada A

PL01
Interorgan Crosstalk in Cardiovascular Physiology and Pathology
Chairpersons: Ichiro Manabe Department of Systems Medicine, Chiba University Graduate School of Medicine
Kenneth Walsh Hemato Vascular Biology Center, Robert M. Berne Cardiovascular Research Center, University of Virginia School of Medicine, USA
State-of-the-Art:
Kenneth Walsh Hemato Vascular Biology Center, Robert M. Berne Cardiovascular Research Center, University of Virginia School of Medicine, USA
Speaker: Yukiteru Nakayama Department of Cardiovascular medicine, Tokyo
Takuya Kishi Department of Graduate School of Medicine (Cardiology), International University of Health and Welfare, Okawa
Soichiro Usui Department of Cardiovascular Medicine, Kanazawa University, Kanazawa
Yumiko Ohishi Department of Medical Biochemistry, Tokyo Medical and Dental University, Tokyo
Chairpersons' Message
The cardiovascular system is controlled within a network of organ systems, including the autonomic nervous, endocrine and metabolic systems, and maintains homeostasis by supplying necessary blood to organs throughout the body. However, this close linkage mechanism can lead to the spread of dysfunction to multiple organs and the cascade of multimorbidity. Much attention has been paid to the inter-organ links, such as cardiorenal, cardiopulmonary and cardiohepatic syndromes. However, heart failure is one of the core diseases of multimorbidity and is bidirectionally associated with many other diseases, including cancer, sarcopenia and psychiatric disorders. The progression of multimorbidity due to this linkage is now a major problem in the treatment and management of patients, particularly the elderly. In addition, SGLT2 inhibitors, RAAS inhibitors or beta-blockers may have beneficial effects on heart failure by acting on multiple organs or their coordination mechanisms. Therefore, there is a need to study heart failure as a systemic disease. In this session, we will discuss the regulation of homeostasis and mutual communication between the cardiovascular system and other organs and systems in cardiovascular diseases, as well as new therapeutic strategies and understanding of the mechanisms that provide a common basis for multiple diseases.

Japanese

Plenary Session 2

March 8 (Fri), 2024 08:00-09:30 Room 9 Kobe International Exhibition Hall No.1 Building 2F Exhibition Hall A

PL02
Developing the health care plan for ACHD in Japan
Chairpersons: Yasushi Sakata Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita
Hirohiko Motoki Department of Cardiovascular Medicine, Shinshu University School of Medicine, Matsumoto
Speaker: Teiji Akagi Department of Cardiovascular Medicine
Yoshihide Mitani Department of Pediatrics, Mie University Graduate School of Medicine, Tsu
Shunsuke Tatebe Department of Cardiovascular Medicine, Tohoku university hospital, Sendai
Tomoko Ishizu Department of cardiology, University of Tsukuba, Tsukuba
Takashi Kido Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita
Chairpersons' Message
Recently, adult patients with congenital heart disease (ACHD) have been facing urgent issues regarding their healthcare system in Japan. Because of the underdeveloped system in our country, pediatric cardiologists keep taking care of the patient's healthcare problems, including hypertension, diabetes mellitus, pregnancy, and mental health. Even though pediatricians are making efforts for patient care, an increasing number of ACHD has already exceeded their capacity. ACHD care has been an established subspecialty in the United States and Europe. The patient care system and the specialists' review board work well in those countries. Japanese adult cardiologists started showing an ACHD care system; however, few models that we can refer to make it challenging to discuss the best plan for ACHD in Japan.
We will discuss the ACHD care system, which has already been launched in some regional areas, and share information about developing the plan for ACHD.

English

Plenary Session 3

March 8 (Fri), 2024 16:25-17:55 Room 3 Kobe Portopia Hotel South Building 1F Ohwada B

PL03
State-of-the-art Strategy for Advanced Heart Failure Using Mechanically Circulatory Support
Chairpersons: Koichiro Kinugawa The Second Department of Internal Medicine, University of Toyama, Toyama
Mandeep R. Mehra Brigham and Women's Hospital and Harvard Medical School, USA
State-of-the-Art:
Mandeep R. Mehra Brigham and Women's Hospital and Harvard Medical School, USA
Speaker: Takuji Kawamura Department of Cardiovascular surgery, Osaka University Graduate School of Medicine, Suita
Madoka Sano Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe
Shuhei Tanaka 2nd Department of Internal Medicine, Toyama
Yoshiyuki Takami Department of Cardiovascular Surgery, Fujita Health University School of Medicine, Toyoake
Chairpersons' Message
Recently, mechanically circulatory support (MCS) has been widely established as a treatment strategy for acute decompensated heart failure as well as stage D heart failure. As percutaneous MCS for cardiogenic shock, line-up of Impella has become more complication-free, and outcome in Japan have been stable. On the other hand, the use of extracorporeal VADs has decreased considerably, and we would like to discuss whether ECPELLA alone is really sufficient. In addition, the concept of interventional HF therapy has been proposed, and we would like to discuss the safe and prompt implementation of other interventions (such TEER) under the support of Impella for patients with advanced heart failure. Finally, destination therapy has finally started to spread in Japan, and I would like to discuss issues such as appropriate patient selection, long-term management issues including hospital-clinic cooperation, and end-of-life care including LVAD deactivation.

English

Plenary Session 4

March 9 (Sat), 2024 08:00-09:30 Room 3 Kobe Portopia Hotel South Building 1F Ohwada B

PL04
Toward Improving the Outcome of Acute Myocardial Infarction with Cardiogenic Shock
Chairpersons: Yuji Ikari Department of Cardiology, Tokai University, Isehara
William O’Neill Henry Ford Hospital, CO-PI Recover Ⅳ Randomized Trial, USA
State-of-the-Art:
William O’Neill Henry Ford Hospital, CO-PI Recover Ⅳ Randomized Trial, USA
Speaker: Makiko Nakamura The Second Department of Internal Medicine, University of Toyama, Toyama
Riku Arai Department: Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo
Natsuhiko Ehara Department Cardiology, Kobe City Medical Center General Hospital, Kobe
Kentaro Jujo Saitama Medical University, Saitama
Shun Kohsaka Department of Cardiology, Keio University School of Medicine, Tokyo
Chairpersons' Message

Primary PCI for acute myocardial infarction has a tremendous lifesaving effect and has reduced the fatality rate in many countries around the world. Among these countries, Japan is known to have the lowest fatality rate of about 3%, resulting in the lowest number of deaths from ischemic heart disease in the world by global comparison.
On the other hand, the mortality rate for acute myocardial infarction with cardiogenic shock remains high, approximately 50%. Of course, mortality was much higher before primary PCI, but the current mortality rate is still a significant problem, and simply performing primary PCI is not effective. New and innovative treatment approaches are needed.
In terms of instrumental support, not only IABP but also ECMO and Impella are now covered by insurance. The effectiveness of this approach is not yet clear, but it is certainly a useful one.
Regarding the method of PCI, it is difficult to perform revascularization in a single procedure in the case of multiple lesions or left main lesions, which are common in patients with cardiogenic shock. Also, in the case of left main lesions, the amount of plaque is large and slow flow due to peripheral embolization is frequent. Re-revascularization methods may also need to be reconsidered.
Furthermore, new ideas in medicine are needed in this area, and we look forward to a discussion on how to improve prognosis in this session.

English

Plenary Session 5

March 9 (Sat), 2024 08:00-09:30 Room 7 Kobe Portopia Hotel South Building B1F Emerald

PL05
Roles of Coagulation Factors and Inflammation in Peripheral Artery Diseases
Chairpersons: Masataka Sata Department of Cardiovascular Medicine, Masataka Sata, Tokushima
Marc P. Bonaca CPC Clinical Research, University of Colorado Anschutz Medical Center, Aurora, Colorado, USA
State-of-the-Art:
Marc P. Bonaca CPC Clinical Research, University of Colorado Anschutz Medical Center, Aurora, Colorado, USA
Speaker: Toshio Takayama Department of Vascular Surgery, The University of Tokyo Hospital, Tokyo
Tomohiro Yamaguchi Department of Cardiovascular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka
Yoshimitsu Soga Department of Cardiology, Kokura Memorial Hospsital, Kitakyushu
Tomoya Hara Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences, Tokushima
Chairpersons' Message

Peripheral artery disease is prevalent, affecting more than 200 million persons worldwide. As a manifestation of systemic atherosclerosis, it is associated with an increased risk of myocardial infarction, stroke, and death from cardiovascular causes, and because of its presence in arteries of the extremities, it impairs walking capacity and may lead to critical limb-threatening ischemia and amputation.2 Yet peripheral artery disease is woefully underrecognized and is often not adequately treated with appropriate evidence-based therapies to preserve life and limb. As compared with patients with known coronary artery disease, patients with established peripheral artery disease only are 30 to 50% less likely to receive antiplatelet drugs, statins, or smoking-cessation interventions.

Recent evidence suggests that low grade activation of coagulation factors may play a role in chronic inflammation of atherosclerotic cardiovascular diseases. In a double-blind trial VOYAGER PAD published in 2020, it was shown that rivaroxaban at a dose of 2.5 mg twice daily plus aspirin was associated with a significantly lower incidence of the composite outcome of acute limb ischemia, major amputation for vascular causes, myocardial infarction, ischemic stroke, or death from cardiovascular causes than aspirin alone, in patients with peripheral artery disease who had undergone lower-extremity revascularization,. The incidence of TIMI major bleeding did not differ significantly between the groups. The incidence of ISTH major bleeding was significantly higher with rivaroxaban and aspirin than with aspirin alone.

In this plenary session, we would like to have presentations about basic and clinical studies on roles of coagulation factors and inflammation in PAD and discuss new directions of PAD management.

English

Plenary Session 6

March 9 (Sat), 2024 10:30-12:00 Room 2 Kobe Portopia Hotel South Building 1F Ohwada A

PL06
Exploring New Frontiers in Management for HFmrEF and HFpEF: Moving Beyond LVEF to a Broader Therapeutic Approach
Chairpersons: Takeshi Kitai Department of Heart Failure and Transplantation, Suita
Carolyn S.P. Lam National Heart Centre Singapore and Duke-National University of Singapore, Singapore
Speaker: Takeshi Kitai Department of Heart Failure and Transplantation, Suita
State-of-the-Art:
Carolyn S.P. Lam National Heart Centre Singapore and Duke-National University of Singapore, Singapore
Speaker: Yuji Nagatomo Department of Cardiology, National Defense Medical College, Tokorozawa
Takao Kato Department of Cardiovascular Medicine, Kyoto University, Kyoto
Eri Kato Department of Cardiovascular Medicine, Kyoto University Hospital, Kyoto
Toru Kondo Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya
Chairpersons' Message
Global aging and advances in diagnostic and therapeutic methods have precipitated a shift in heart failure phenotypes. An increased prevalence of heart failure with preserved ejection fraction (HFpEF) is reported, and understanding of heart failure with mildly reduced ejection fraction (HFmrEF) is expanding.
The therapeutic arsenal for HFrEF patients has expanded to include Quadruple therapy (beta-blockers, ARNI, SGLT2 inhibitors, mineralocorticoid receptor antagonists), If channel blockers, and sGC stimulants. SGLT2 inhibitors have shown promise for HFpEF, with emerging evidence for ARNI and MRA. Pharmacotherapy could potentially enhance outcomes for HFmrEF and HFpEF where LVEF approximates the lower limit of normality. However, therapeutic efficacy for patients maintaining normal LVEF may be diminished, suggesting limitations of classifying solely based on LVEF.
In this symposium, we aim to revisit therapeutic targets from the perspectives of pharmacological mechanisms and supporting evidence. Discussions will explore adaptability of heart failure treatments, moving beyond LVEF and encompassing the broader pathophysiological landscape of heart failure.

English

Plenary Session 7

March 9 (Sat), 2024 13:30-15:00 Room 4 Kobe Portopia Hotel South Building 1F Ohwada C

PL07
Imaging of Cardiomyopathy Update (Including Pathology)
Chairpersons: Hajime Sakuma Department of Radiology, Mie University
Patricia A. Pellikka Mayo Clinic; Journal of the American Society of Echocardiography, USA
State-of-the-Art:
Patricia A. Pellikka Mayo Clinic; Journal of the American Society of Echocardiography, USA
Speaker: Kenichi Hongo Division of Cardiology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo
Hiroki Usuku Department of laboratory medicine, Kumamoto University Hospital, Kumamoto
Shiro Nakamori Department of Cardiology and Nephrology, Tsu
Yoshinori Yoshida Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application, Kyoto University, Kyoto
Chairpersons' Message
In the 2021 ESC guidelines, echocardiography, plain chest radiographs and cardiac magnetic resonance imaging (CMR) are Class I non-invasive imaging modalities for patients with heart failure are. Echocardiography is the primary method of assessing cardiac function, providing information on left and right ventricular volumes and ejection fraction, left ventricular hypertrophy and regional wall motion abnormalities, as well as information on diastolic function, which is difficult to assess with CMR. In contrast, CMR can demonstrate cardiac morphology and function in patients for whom echocardiography does not provide good images. In addition, late gadolinium enhanced MRI and T1 mapping can provide myocardial histopathological information with relatively good specificity in patients with Fabry disease, amyloidosis, sarcoidosis and suspected haemochromatosis. T2 mapping is an imaging technique that can demonstrate myocardial edema that cannot be correctly diagnosed by T1 mapping alone. CMR study including T2 mapping is an essential test for the diagnosis of myocarditis, takotsubo cardiomyopathy and MINOCA. FDG-PET is useful for the assessment of cardiac sarcoidosis activity, and contrast enhanced cardiac CT can reveal not only coronary arterial stenosis but also information related to myocardial tissue characterization, such as fibrosis and quantification of extracellular fluid fractions. In this session, experts will present the latest information on latest imaging techniques and pathology of cardiomyopathies, and will also discuss the challenges of making such imaging techniques widely available nationwide.

English

Plenary Session 8

March 9 (Sat), 2024 13:30-15:00 Room 9 Kobe International Exhibition Hall No.1 Building 2F Exhibition Hall A

PL08
Current Status of Cardiovascular Emergencies and Proposals for Resolving the Issues
Chairpersons: Yoshio Tahara Department of Cardiovascular Emergency, National Cerebral and Cardiovascular Center, Suita
Takahiro Nakashima Emergency Medicine, University of Michigan, United States of America
State-of-the-Art:
Takahiro Nakashima Emergency Medicine, University of Michigan, United States of America
Speaker: Ken Saito Department of Cardioly, National Cerebral and Cardiovascular Center, Suita
Hidetoshi Hattori Department of Cardiology, Tokyo Women's Medical University, Tokyo
Yuichiro Kashima Department of Emergency and Critical Care Medicine, Shinshu University, Matsumoto
Takuma Ishibashi The University of Tokyo, Faculty of Medicine, Tokyo
Chairpersons' Message
In December 2018, the Basic Act on Measures to Stroke and Cardiovascular Disease was enacted. Since then, interest and expectations for cardiovascular emergencies have increased.
Cardiovascular emergencies include acute myocardial infarction, acute heart failure, and acute aortic dissection. Hyperacute care for these diseases is a race against time, and it is important to establish an emergency transport system in which patients are transported to a hospital that can treat them based on appropriate judgment at the emergency scene. In addition, the hospital to which the patient is transported needs to start appropriate treatment as soon as possible after the onset of the disease, and it is necessary to provide optimal treatment for each case, including drug therapy, catheterization, and surgical treatment, and to establish an emergency medical care system that includes a multidisciplinary treatment system in intensive care units, including the use of mechanical circulatory assist devices in cases of cardiogenic shock complications.
In order to establish an emergency transport system, it is necessary to improve hospital selection by appropriately linking hospital information such as available beds and emergency activity information, and it is important to promptly consolidate such information to the appropriate specialty hospitals using information and communication technology such as 12-lead electrocardiogram transmission by emergency services. Especially in regions where medical care is unevenly distributed, it is essential to establish networks through wide-area collaboration such as doctor helicopters.
Issues to be addressed to improve the acute care system include education of ambulance crew, human resource development of physicians involved in emergency medicine, improvement of the work system, definition and appropriate placement of highly specialized hospitals, improvement of the emergency transport system, and coordination of medical institutions in the region.
In this session, the speakers will introduce the efforts being made in each region to address cardiovascular emergencies. We will also present proposals for solving issues based on an understanding of the current status of cardiovascular emergencies.

English

Plenary Session 9

March 9 (Sat), 2024 16:25-17:55 Room 2 Kobe Portopia Hotel South Building 1F Ohwada A

PL09
Digital Transformation for the Future of Cardiovascular Health
Chairpersons: Akihiro Nomura College of Transdisciplinary Sciences for Innovation, Kanazawa University, Kanazawa
Joost Lumens CARIM Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, The Netherlands
State-of-the-Art:
Joost Lumens CARIM Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, The Netherlands
Speaker: Atsuko Nakayama Department of Cardiology, Sakakibara Heart Institute, Tokyo
Ryoko Uchida Department of Advanced Cardiology The University of Tokyo, Tokyo
Toshiyuki Nagai Department of Cardiovascular Medicine, Hokkaido University, Sapporo
Isao Shiraishi National Cerebral and Cardiovascular Center, Suita
Chairpersons' Message
Digital Health embodies the application of digital technology across medical, caregiving, and health support activities using Information and Communication Technology (ICT). Digital Transformation (DX) in medicine encompasses the aggregation, integration, and optimization of all data generated in the processes of medicine, care, and health. Appropriately utilized, the processed data can aid in disease prevention, enabling individuals to receive enhanced medical care and healthcare. Additionally, DX signifies a series of initiatives aimed at improving not only the healthcare sector but also society in a broader sense. Cardiovascular health in the era of DX denotes the advancement of medical DX within the field of cardiovascular medicine. Traditional cardiovascular care is being reshaped in myriad ways due to factors such as the easy accessibility to abundant computational resources, the significant progress of machine learning algorithms, the effective usage of large-scale public medical databases, and fostering the development of new treatment strategies such as digital therapeutics. In this plenary session, leading experts in cardiovascular digital health will present lectures on their research, device innovation, and societal implementation strategies intended to mitigate cardiovascular diseases by deploying various state-of-the-art digital technologies. This session is not limited to the promotion of DX in cardiovascular medical practices, but also extends to primary prevention and intervention at pre-symptomatic stages in the field of care and health. It is a timely moment to present the upcoming future of digitally-transformed cardiovascular health.

English

Plenary Session 10

March 9 (Sat), 2024 16:25-17:55 Room 3 Kobe Portopia Hotel South Building 1F Ohwada B

PL10
New Technology for Non-Pharmacological Treatment of Arrhythmias
Chairpersons: Morio Shoda Department of Cardiology, Tokyo Women's Medical University, Tokyo
Hiroshi Nakagawa Department of Cardiovascular Medicine, Cleveland Clinic, USA
State-of-the-Art:
Hiroshi Nakagawa Department of Cardiovascular Medicine, Cleveland Clinic, USA
Speaker: Atsushi Suzuki Department of Cardiology, Yodogawa Christian Hospital., Osaka
Shiro Nakahara Department of Cardiology, Dokkyo Medical University Saitama Medical Center, Koshigaya
Satoshi Higuchi Department of Cardiology, Tokyo Women’s Medical University, Shinjuku-ku, Tokyo
Marjolein De Jongh Cardiology, Haga Teaching Hospital, The Netherlands
Mari Amino Department of Cardiology, Tokai University, Isehara
Chairpersons' Message

In 1983, catheter ablation was first reported as a treatment for arrhythmia. Around 1990, the method shifted to safe radiofrequency ablation, followed by cryoablation, laser ablation, and more recently, PFA (Pulse Field Ablation) has recently emerged. The development of CARTO, a three-dimensional mapping method for arrhythmias, began in 1993, and was followed by methods such as LocaLisa (now EnSite).
The surgical maze method for atrial fibrillation was reported in 1990, a landmark case in which surgeons achieved a fibrillatory arrhythmia that was thought to be untreatable. Since then, atrial fibrillation ablation methods have continued to evolve over the past 30 years.
Arrhythmia device therapy has also seen one technological innovation after another, with the advent of fully implantable pacemakers in 1960, implantable defibrillators in 1980, cardiac resynchronization therapy around 2000, and leadless pacemakers and subcutaneous implantable defibrillators in clinical use today, Implanted patients are now managed with remote monitoring.
Thus, arrhythmia non-pharmacologic therapy has evolved along with new technological innovations, and surprisingly, the progress has not stopped. In this plenary session, we will look ahead to the near future of arrhythmia therapy, 60 years after the advent of pacemakers, 40 years after catheter ablation, and 30 years after Maze surgery.

English

Plenary Session 11

March 9 (Sat), 2024 16:25-17:55 Room 4 Kobe Portopia Hotel South Building 1F Ohwada C

PL11
Updates on the Pathophysiology, Diagnosis, and Treatment for Takayasu Arteritis
Chairpersons: Yoshikazu Nakaoka Department of Vascular Physiology,, National Cerebral and Cardiovascular Center Research Institute, Suita
Peter A. Merkel Division of Rheumatology, Department of Medicine and Division of Epidemiology, Department of Biostatistics, Epidemiology, and Informatics, Hospital of the University of Pennsylvania, USA
State-of-the-Art:
Peter A. Merkel Division of Rheumatology, Department of Medicine and Division of Epidemiology, Department of Biostatistics, Epidemiology, and Informatics, Hospital of the University of Pennsylvania, USA
Speaker: Tsuyoshi Shirai Tohoku University Hospital, Sendai
Shun Nakagama Department of Cardiovascular Medicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo
Yoshikazu Nakaoka Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute, Suita
Yo Arita Department of Cardiology, Japan Community Healthcare Organization (JCHO) Osaka Hospital, Osaka
Chairpersons' Message
Takayasu arteritis (TAK) is a large vessel vasculitis that mainly affects the aorta and its primary branches. The principal manifestations of TAK are systemic inflammation, pain due to vasculitis, and vascular stenosis, occlusion, and dilatation, and poses problems including disorders of various organs due to disturbance of the blood flow and aneurysms. Since its symptoms are diverse and non-specific, some patients with TAK still need longer time for diagnosis. Although TAK is estimated to be caused by autoimmune mechanisms, the precise mechanisms underlying this disease has been elusive. Some genetic variants associated with TAK have been reported and the basic researches focusing on these genetic association have been performed. Currently, there are no specific findings on blood or biological tests for the diagnosis of TAK. Therefore, non-specific indices of inflammation including CRP and ESR are used as the biomarkers for the diagnosis of TAK. The diagnosis of TAK is made primarily by imaging tests including CT, MRI, ultrasonography, and FDG-PET/CT. Impressive progresses has been achieved in the medical treatment for TAK. Biologic agents including anti-IL-6 receptor antibody tocilizumab and anti-TNF inhibitors have been widely used for treatment of TAK in Japan. Since there are still many patients who need to undergo surgical treatment and endovascular therapy for aortic aneurysms and aortic regurgitation, we need to know adequate management of surgical and endovascular treatments. In this session, we would like to share and discuss the recent progress of basic research, epidemiology, diagnosis, medical and invasive treatments for TAK.

English

Plenary Session 12

March 9 (Sat), 2024 16:25-17:55 Room 9 Kobe International Exhibition Hall No.1 Building 2F Exhibition Hall A

PL12
The Significance of Multi-modality Imaging in Pulmonary Hypertension Guideline Update
Chairpersons: Mitsushige Murata Department of Laboratory Medicine, Tokai University Hachioji Hospital, Tokyo
Marc Humbert University Paris-Saclay, France
State-of-the-Art:
Marc Humbert University Paris-Saclay, France
Speaker: Katsuji Inoue Department of Cardiology, Pulmonology, Hypertension & Nephrology, Ehime University Graduate School of Medicine, Toon
Takahiro Hiraide Department of Cardiology, Keio University School of Medicine, Tokyo
Kohtaro Abe Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka
Masafumi Fukumitsu Department of Cardiovascular Dynamics, National Cerebral and Cardiovascular Center, Suita
Chairpersons' Message
The 2022 ESC/ERS Pulmonary Hypertension (PH) Guidelines specifically present diagnostic algorithms that actively utilize imaging modalities and parameters for the prediction of prognosis, emphasizing the use of imaging modalities in the PH diagnosis. Among the imaging modalities, echocardiography has the most evidence and is recommended as the first line examination in suspected PH cases. Especially for PH screening, it was emphasized to evaluate the possibility of PH from the right ventricular (RV) morphology and function in addition to the conventional estimation of pulmonary artery pressure. Notably, the guideline recommended that the parameter of RV-PA coupling should be measured as well.
However, cardiac magnetic resonance imaging has high reproducibility in measuring the volume of the right ventricle and ejection fraction, and is useful for the prediction of prognosis in PH. In addition, it enables non-invasive hemodynamic evaluation of PH by analyzing the pulmonary artery and right ventricular blood flow, and further accumulation of data is needed in the future. In this guideline, the definition of PH was revised downward to the mean pulmonary artery pressure (mPAP) of 20 mmHg or more, thus, re-evaluation of PH screening, pathological conditions, and prognostic prediction should be performed by the imaging modalities. In this symposium, we would like to review the update of diagnostic imaging in PH guidelines and how to use it in daily clinical practice, and also to deepen the discussion on the issues and future directions.

English

Plenary Session 13

March 10 (Sun), 2024 08:00-09:30 Room 4 Kobe Portopia Hotel South Building 1F Ohwada C

PL13
Recent Progress in Diagnosis and Treatment of Ischemic Heart Disease via Coronary Artery Imaging
Chairpersons: Toshiro Shinke Division of Cardiology, Department of Medicine, Showa University School of Medicine, Tokyo
Yasuhiro Honda Stanford University School of Medicine, USA
State-of-the-Art:
Yasuhiro Honda Stanford University School of Medicine, USA
Speaker: Kota Murai Division of Coronary Diseases, Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita
Kenichiro Otsuka Department of Cardiovascular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka
Kensuke Nishimiya Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai
Toshiro Kitagawa Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima
Hiromasa Otake Division of Cardiovascular Medicine, Department of Internal Medicine,Kobe University Graduate School of Medicine , Kobe
Chairpersons' Message

Recently, there have been significant advancements in the diagnosis and treatment of ischemic heart disease, and coronary artery imaging has played a crucial role in this progress. In the past era when the clinical management of coronary artery disease relied solely on coronary angiography, understanding the pathophysiology of coronary artery disease was largely dependent on pathological examinations. However, the clinical application of intravascular ultrasound, intravascular endoscopy, and optical coherence tomography has provided substantial evidence regarding the development, progression, vulnerable changes, and mechanisms of acute coronary syndromes, as well as disease stabilization achieved through medical treatment. These advancements have also greatly contributed to optimizing percutaneous coronary artery interventions.
Furthermore, the technological advancements in cardiac CT and MRI have brought about significant changes in the healthcare managements, playing a crucial role in diagnosing the presence and severity of diseases, predicting prognosis, and selecting appropriate intervention strategies. This session aims to provide a platform for sharing the latest knowledge not only on invasive coronary artery imaging but also on non-invasive diagnostic techniques. We welcome a wide range of submissions and aim to offer cutting-edge medical science to physicians and medical staff involved in cardiovascular medicine.

English

Plenary Session 14

March 10 (Sun), 2024 13:20-14:50 Room 3 Kobe Portopia Hotel South Building 1F Ohwada B

PL14
Brain-heart Team Approach for Stroke Prevention
Chairpersons: Hidehiko Hara Division of Cardiovascular Medicine, Toho University Ohashi Medical Center , Tokyo
Eustaquio Maria Onorato IRCCS Unversity Dept, Galeazzi Sant'Ambrogio Hospital, Italy
State-of-the-Art:
Eustaquio Maria Onorato IRCCS University Cardiology Dept, Galeazzi Sant’Ambrogio Hospital, Italy
Speaker: Taiji Okada Department of Cardiology, Kobe City Medical Center General Hospital, Kobe
Takashi Miki Department of Cardiovascular Medicine, Okayama University Hospital, Okayama
Mikio Shiba Cardiovascular Division, Osaka Police Hospital, Osaka
Masato Fukunaga Department of Cardiology, Kokura Memorial Hospital, Kitakyushu
Chairpersons' Message
In Japan, 5 years have passed since the introduction of cardiovascular catheter interventions for prevention of cerebral infarction. Along with worldwide evidence, those treatments that had not received much attention in Japan 10 years ago have been recognized recently, and they have finally penetrated little by little. This is a treatment that has already started more than 20 years ago in Europe, and more than 15 years have passed since the device was approved. The concept of the Brain Heart Team is especially important for the spread of this treatment. This is the heart team approach that has spread overseas in the area of coronary artery disease firstly ( a concept that was originally used to determine the indications for CABG or PCI, nowadays between SAVR and TAVI). From the perspective of stroke prevention, it is important to form a team of stroke specialists consisting of neurologist or neurosurgeon with cardiologist, especially interventional cardiologist and imaging specialist. So, we are planning to invite Dr. Onorato from Italy to give us a key-note lecture who firstly has prevailed this brain-heart team concept in the world. In addition, in the RESPECT study, which proved the usefulness of percutaneous patent foramen ovale closure, especially in the United States, this Brain-heart team approach was further recommended when considering to close the PFO by AMPLATZER PFO occluder by the FDA. In Japan, involvement of stroke specialist was also recommended by the working group constructed with associations related with percutaneous left atrial appendage closure. Here, I would like to create a session that can make this Brain-heart team approach much productive in Japan through cross-talk between stroke specialists and cardiologists involved in this treatment.

English

Plenary Session 15

March 10 (Sun), 2024 15:30-17:00 Room 3 Kobe Portopia Hotel South Building 1F Ohwada B

PL15
Total Management of Atrial Fibrillation Associated with Heart Failure with Preserved Ejection Fraction (HFpEF)
Chairpersons: Kyoko Soejima Department of Cardiovascular Medicine, Kyorin University, Tokyo
Carlo de Asmundis Heart Rhythm Management Centre, Postgraduate Program in Cardiac Electrophysiology and Pacing, Universitair Ziekenhuis Brussel - Vrije Universiteit Brussel, European Reference Networks Guard-Heart, Brussels, Belgium
State-of-the-Art:
Carlo de Asmundis Heart Rhythm Management Centre, Postgraduate Program in Cardiac Electrophysiology and Pacing, Universitair Ziekenhuis Brussel - Vrije Universiteit Brussel, European Reference Networks Guard-Heart, Brussels, Belgium
Speaker: Yasuhiro Hamatani Department of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto
Atsushi Kobori Department of Cardiology, Kobe City Medical Center General Hospital, Kobe
Shingo Maeda Arrhythmia Advanced Therapy Center, AOI Universal Hospital, Kawasaki
Shonosuke Watanabe Department of cardiology, Saiseikai Kawaguchi General Hospital, Saitama
Chairpersons' Message

Total management of Atrial Fibrillation Associated with heart failure with preserved ejection fraction (HFpEF)

Atrial fibrillation and HFpEF are highly prevalent cardiovascular conditions, and frequently coexist. Risk factors that predispose to AF are similar in HFpEF, including hypertension, coronary heart disease, diabetes mellitus, CKD, obesity, alcohol consumption, aging. They are often called as “vicious twins”.  We need to make effort for early diagnosis and early rhythm management for AF, and prevent the HF progression at the early stage. In this session, we would like to discuss the total management of atrial fibrillation associated with HFpEF.

Symposium

Japanese

Symposium 1

March 8 (Fri), 2024 08:00-09:30 Room 3 Kobe Portopia Hotel South Building 1F Ohwada B

SY01
Palliative Care and Japanese Community-based Integrated Care System
Chairpersons: Yukihito Sato Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center
Takayuki Inomata Department of Cardiovascular Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata City
Takashi Kohno Department of Cardiovascular Medicine, Mitaka
Speaker: Takuma Sato Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo
Sho Okada Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba
Yuhei Shiga Department of Cardiology, Fukuoka University School of Medicine, Fukuoka
Shogo Oishi Department of Cardiology, , Mahoshi hospital, Kobe
Taiki Higo Yumino Heart Clinic, Tokyo
Chairpersons' Message

Heart failure (HF) is the end stage of cardiac disease. Despite the introduction of new and more effective pharmacological and nonpharmacological therapies, the mortality rate from heart failure is still high. Initially, the main treatment goals are to improve clinical outcomes, reduce mortality, and minimize hospitalizations. However, the primary goal may change at the end stage of heart failure, with quality of life (QOL) becoming particularly important. Many patients diagnosed with HF experience symptoms that affect their QOL. Therefore, several international cardiology professional organizations have recommended that palliative care (PC) be incorporated as a treatment option for patients with HF. Recently, the Palliative Care in Heart Failure (PAL-HF) study revealed that interdisciplinary palliative care intervention in advanced HF patients showed consistently greater benefits in QOL, anxiety, depression, and spiritual well-being than usual care alone. A systematic review revealed that compared with usual care, PC interventions were associated with a substantial reduction in hospitalizations, although there was no clear adverse impact on mortality. In Japan, multidisciplinary team-based PC for HF was not reimbursed by April 2018, and only a few JCS-authorized cardiology training hospitals have a PC team for HF. In October 2019, the Heart Failure Palliative Care Training program for comprehensive care providers (HEPT) was officially approved by the JHFS. The JCS/JHFS released the 2021 statement on palliative care for cardiovascular diseases.

Recently, approximately 55% of the general population in Japan hopes to die at home. However, the number of deaths in Japan is expected to increase, and hospital bed capacity as a place of death is predicted to be in short supply. To fill this gap, the Japanese government has, since 2006, promoted end-of-life care at home and long-term care insurance (LTCI) facilities by increasing financial incentives for service providers who attend to patients’ deaths at home and at LTCI facilities, expecting appropriate end-of-life care outside the hospital is expected to reduce in-hospital deaths. In this symposium, palliative care in Japanese community-based integrated care will also be discussed.

Japanese

Symposium 2

March 8 (Fri), 2024 08:00-09:30 Room 4 Kobe Portopia Hotel South Building 1F Ohwada C

SY02
Development of Cardiovascular Critical Care by the Tele-ICU/CCU
Chairpersons: Hiroshi Imamura Department of Emergency and Critical Care Medicine, Shinshu University, Matsumoto
Tomonori Itoh Division of Cardiology, Department of internal Medicine/ Division of Community Medicine, Department of Medical Education, Iwate Medical University
Speaker: Shunsuke Takaki Department of Critical Care Medicine, Yokohama City University School of Medicine , Yokohama
Takeshi Yamamoto Division of Cardiovascular Intensive Care, Nippon Medical School Hospital, Tokyo
Yoshio Tahara Department of Cardiovascular Emergency, National Cerebral and Cardiovascular Center, Suita
Kazuki Kikuyama Department of Intensive Care Unit, Showa University School of Medicine, Tokyo
Seita Kondo Division of Cardiology, Department of Medicine, Showa University School of Medicine, Tokyo
Chairpersons' Message
Telemedicine intensive care unit (Tele-ICU) is the use of an off-site command center in which intensivists and critical care nurses are connected with patients in distant ICUs to exchange health information via electronic communications. Tele-ICU has been developed through the advances in information technology, the complexity of today’s ICU services, and a shortage of intensivists. It has become more popular during the COVID-19 pandemic. Tele-ICU/CCU system could play a significant role to improve, standardize, and sustain the quality of cardiovascular critical care in Japan. In this joint symposium of JCS and JSICM, cardiologists, intensivists, and cardiovascular intensivists would discuss the current status and future prospects of the Tele-ICU/CCU.

Collaborated with The Japanese Society of Intensive Care Medicine

Japanese

Symposium 3

March 8 (Fri), 2024 08:00-09:30 Room 7 Kobe Portopia Hotel South Building B1F Emerald

SY03
Pathogenic Evaluation and Therapeutic Strategies Based on the New Definition of Pulmonary Hypertension
Chairpersons: Yoshihiro Fukumoto Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine, Kurume
Masaharu Kataoka The Second Department of Internal Medicine, University of Occupational and Environmental Health
Speaker: Noriaki Takama Department of Cardiovascular Medicine, Maebashi
Kohshi Setoyama The 2nd Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu
Hirofumi Sawada Department of Pediatrics, Mie University School of Medicine, Tsu
Taijyu Satoh Department of cardiovascular medicine, Tohoku university graduate school of medicine, Sendai
Takumi Inami Department of Cardiovascular Medicine, Kyorin University School of Medicine, Tokyo
Yudai Tamura Cardiovascular center, International University of Health and Welfare Mita Hospital, Tokyo
Chairpersons' Message
The European guideline for pulmonary hypertension was revised in 2022, with a new definition of pulmonary hypertension. The criteria value of mean pulmonary arterial pressure at rest was lowered to 20 mmHg, and the exercise pulmonary hypertension was newly defined. In Japan, the clinical diagnostic criteria for pulmonary hypertension have been recognized as the criteria of the designated intractable diseases, indicating that the new definition is dissociated from the diagnostic criteria for pulmonary hypertension treatment. It should be noted that the evidence for treatment for pulmonary arterial hypertension (PAH) have been made based on the previous definition, which is also specified in the revised European guideline. Furthermore, the revised European guideline proposed the new disease name “chronic thromboembolic pulmonary disease (CTEPD)”, which includes the conventional “chronic thromboembolic pulmonary hypertension”, and the importance of diagnose and treatment for not only CTEPD with PH but also CTEPD without PH, specifically in patients with a history of acute pulmonary thrombosis, and the expansion of indication for balloon pulmonary angioplasty for CTEPD without PH were recommended. Based on the revised European definition, we would like to discuss in this symposium, how the pathogenesis of pulmonary hypertension should be evaluated more accurately, how treatment strategies should be adopted, how to screen and perform genetic counseling for at-risk population for PAH, such as patients with connective tissue diseases and blood relatives of patients with heritable pulmonary arterial hypertension, and how CTEPD, in which the number of patients is expected to increase, should be managed.

Japanese

Symposium 4

March 8 (Fri), 2024 08:00-09:30 Room 10 Kobe International Exhibition Hall No.1 Building 2F Exhibition Hall B

SY04
Sudden Cardiac Death; Frontiers in Diagnosis, Prevention and Treatment
Chairpersons: Wataru Shimizu Department of Cardiovascular Medicine, Nippon Medical School, Tokyo
Taku Iwami Department of Preventive Services, Kyoto University Graduate School of Medicine
Speaker: Hiroshi Morita Department of Cardiocascular Therapeutics, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama Universit, Okayama
Megumi Fukuyama Department of Cardiovascular Medicine, Shiga University of Medical Science, Otsu
Yasuyuki Shiraishi Department of Cardiology, Keio University School of Medicine, Tokyo
Toshinori Chiba Chiba University Graduate School of Medicine, Chiba
Yasuki Hen Department of Cardiology, Sakakibara Heart Institue Clinic, Tokyo
Chika Nishiyama Department of Critical Care Nursing, Graduate School of Medicine, Kyoto University, Kyoto
Chairpersons' Message
Most deaths from cardiovascular disease occur suddenly outside the hospital, with over half of acute coronary syndrome (ACS)-related deaths happening out-of-hospital settings. In Japan, more than 70,000 cases of sudden cardiac death (SCD) occur each year. To reduce SCDs, it is crucial for individuals encountering sudden cardiac arrest to provide life support measures using automated external defibrillators (AEDs), improve pre-hospital emergency medical care provided by emergency medical personnel, and enhance intensive care following the return of spontaneous circulation. The Japanese Society of Cardiology is taking a comprehensive approach to address this issue. On the medical front, we focus on preventing arrhythmic deaths by employing implantable cardioverter-defibrillators (ICDs), promoting percutaneous coronary intervention (PCI) as a treatment for ACSs, and improving post-resuscitation intensive care. Simultaneously, we are actively engaging the public by promoting the use of AEDs, advocating the CALL and PUSH campaign to encourage chest-compression-only cardiopulmonary resuscitation (CPR), and raising awareness about angina pectoris symptoms as a warning sign for acute myocardial infarction (Stop MI campaign). In recent years, significant progress has been made in preventing and predicting SCD, a challenge that was previously deemed difficult. This has been achieved through the development of genomic medicine to prevent fatal arrhythmias, the implementation of ICDs and wearable cardioverter-defibrillators (WCDs) to prevent arrhythmic deaths, and the utilization of wearable devices and personal health records (PHRs). In this session, we aim to provide an update on a wide range of strategies to prevent SCD, including life-saving measures after cardiac arrest, prevention strategies for fatal arrhythmias and ischemic heart disease, and raising public awareness of emergency medical services. Through this session, we hope to expedite the implementation of measures against SCD.

Japanese

Symposium 5

March 8 (Fri), 2024 09:30-11:00 Room 2 Kobe Portopia Hotel South Building 1F Ohwada A

SY05
Current Status and Future Perspectives of Genome Medicine for Cardiovascular Disease
Chairpersons: Yoshihiro Asano National Cerebral and Cardiovascular Center/Osaka University, Suita
Hayato Tada Department of Cardiology, Kanazawa University Hospital, Kanazawa
Speaker: Hayato Tada Department of Cardiology, Kanazawa University Hospital, Kanazawa
Takeshi Aiba National Cerebral and Cardiovascular Center, Suita
Yohei Miyashita Department of Genomic Medicine, National Cerebral and Cardiovascular Center, Suita
Kazuhiro Kimura Department of cardiology, Shinshu University School of Medicine, Matsumoto
Takahiko Nishiyama Department of Cardiology, Keio University School of Medicine, Tokyo
Chairpersons' Message

Many cardiovascular diseases are heritable traits, and it is self-evident that genomic medicine for cardiovascular diseases is important. In Japan, genetic testing for about 200 diseases, including cardiovascular diseases (intractable diseases, etc.), is now covered by insurance, and genomic medicine is becoming more familiar. In this symposium, we will introduce advances in the field of genomic medicine in the field of cardiovascular disease, in addition to advances in actual clinical practice, such as indications for genetic testing, application to clinical practice (diagnosis and personalized medicine), and counseling. We would like to have a place to share and deepen discussions on research, medical treatment, policy, etc. about future issues. It is also self-evident that in the near future, various dimensions of genomic medicine will be incorporated into standard medical care in the field of cardiovascular disease, as is the case with the current so-called cancer genomic medicine. It is hoped that this symposium will serve as an opportunity to greatly stimulate cardiologists, who have been relatively unfamiliar with cardiovascular genomic medicine, and to serve as an opportunity for further development of this field in Japan.

Japanese

Symposium 6

March 8 (Fri), 2024 13:30-15:00 Room 6 Kobe Portopia Hotel South Building B1F Topaz

SY06
How Specifically can we Diagnose the INOCA Endotypes?
Chairpersons: Ken Kozuma Department of Cardiology, Teikyo University, Tokyo
Kenichi Tsujita Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto
Speaker: Akira Taruya Department of Cardiovascular Medicine, Wakayama Medical University, Wakayama
Akiko Sakai Department of Cardiology, Tokyo Women’s Medical University, Tokyo
Yuichi Saito Department of Cardiovascular Medicine, Chiba
Hirohiko Ando Department of Cardiology, Aichi Medical University, Nagakute
Jun Takahashi Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai
Chairpersons' Message
Coronary microvascular dysfunction (CMD) has drawn much more attention as a cause of ischemic symptom. Our international study group, COVADIS (the Coronary Vasomotor Disorders International Study), also showed that microvascular angina (MVA) is an important health problem with higher risk of MACE regardless of sex or ethnicity. Furthermore, CMD is related to the pathophysiology, mortality, and morbidity of heart failure with preserved ejection fraction (HFpEF). How frequently does CMD exist in patients with HFpEF?
On the other hand, CorMicA trial showed that the IDP (interventional diagnostic procedure)-based stratified treatment regimen could improve the chest symptom and quality of life (e.g. Seattle angina score).
However, there is practical limitations in the real-world practice situation. How can we diagnose the presence of INOCA in patients with angina? Which should be performed first, acetylcholine provocation test? Or coronary microvascular function? How can we detect the INOCA with non-invasive modalities? Cardiac rehabilitation would really attenuate the INOCA symptom?
In this session, we would like to tackle with these problems with the experts, discussants and audience.

English

Symposium 7

March 8 (Fri), 2024 16:25-17:55 Room 2 Kobe Portopia Hotel South Building 1F Ohwada A

SY07
Myocarditis in 2024: Updates in Diagnosis and Management
Chairpersons: Kazufumi Nakamura Department of Cardiovascular Medicine, Okayama University, Okayama
Toshiyuki Nagai Department of Cardiovascular Medicine, Hokkaido University, Sapporo
Speaker: Naofumi Amioka Department of Cardiovascular Medicine, Okayama University Hospital, Okayama
Takahiro Okumura Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya
Koshiro Kanaoka Department of Medical and Health Information Management, National Cerebral and Cardiovascular Center, Suita
Kazuko Tajiri Department of Cardiology, National Cancer Center Hospital East, Kashiwa
Taku Omori Department of Cardiology, Mie University Hospital, Tsu
Chairpersons' Message
In the last decade, advances in histopathological and viral genome analyses have led to a better understanding of the pathophysiology of myocarditis, resulting in significant changes in disease concepts, and classifications, primarily in Europe and the United States. In terms of diagnosis, following the remarkable improvement in the diagnostic accuracy of cardiac MRI, statements and consensus have been published stating that clinical scenarios may not necessarily require myocardial tissue evaluation through endomyocardial biopsy. Additionally, in terms of treatment, randomized controlled trials suggesting the effectiveness of immunosuppressive therapy for viral genome-negative myocarditis, including long-term outcomes, have been reported. Also, there are preliminary studies suggesting the effectiveness of antiviral therapy. Last year, the Japanese Circulation Society guideline on the diagnosis and treatment of myocarditis was revised, proposing a new classification with a focus on risk stratification in the chronic phase of myocarditis, based on the data from Japanese patients while following the global trends. One year has passed since the publication of the guideline, and it has gradually started to be implemented in clinical practice. However, there are still many challenges in identifying patients with myocarditis who can actually be treated. In this symposium, we would like to once again share the current status on the management of myocarditis based on the updated evidence, and deepen the discussion on personalized treatment for myocarditis through a multidimensional approach involving histopathology, genomics, imaging, and other aspects.

Japanese

Symposium 8

March 8 (Fri), 2024 16:25-17:55 Room 7 Kobe Portopia Hotel South Building B1F Emerald

SY08
Optimal Antithrombotic Therapy for Japanese Patients
Chairpersons: Shinya Goto Department of Medicine(Cardiology) Tokai University School of Medicine
Gaku Nakazawa Kindai University Hospital, Osaka-sayama
Speaker: Toshiaki Toyota Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe
Satoshi Yasuda Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai
Hirofumi Tomita Department of Cardiology and Nephrology, Hirosaki University Graduate School of Medicine, Hirosaki
Hideki Kitahara Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba
Kazuhisa Kaneda Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto
Chairpersons' Message
Arteriosclerotic diseases are on the rise in Japan as a result of the aging of the population and the westernization of lifestyles. It goes without saying that antithrombotic therapy plays an important role in preventing the various organ failures and deaths caused by intravascular thrombi that occur in arteriosclerotic diseases. However, it is not easy to find an optimal approach for Japanese patients, taking into account individual patient characteristics, culture, and genetic factors. Antithrombotic therapy nowadays is used for a variety of thromboses, including intracoronary thrombi in acute coronary syndromes, thrombi in atrial fibrillation, and arterial and venous thrombi in lower extremity arteries. The main objective of this session is to share the latest research results and clinical experiences and to explore the prospects for optimal antithrombotic therapy in the Japanese population, which is characterized by a low risk of thrombosis and a high risk of bleeding compared to Western populations. By bringing together our knowledge and expertise, through discussion and information exchange, we will be able to identify more effective and safer treatment options. We hope that speakers with different specialties and experiences will share their valuable insights and provide an opportunity to discuss optimal antithrombotic therapy for the Japanese population.

English

Symposium 9

March 8 (Fri), 2024 16:25-17:55 Room 10 Kobe International Exhibition Hall No.1 Building 2F Exhibition Hall B

SY09
Current Situation of Aortic Annular Enlargement
Chairpersons: Hirofumi Takemura Department of Cardiovascular Surgery, Kanazawa University
Kenji Minatoya Department of Cardiovascular Surgery, Kyoto University
Speaker: Naosumi Sekiya Department of Cardiovascular Surgery, Sakurabashi Watanabe Hospital, Osaka
Koichi Maeda Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita
Tomohiko Taniguchi Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe
Tadashi Kitamura Department of Cardiovascular Surgery, Kitasato University School of Medicine, Sagamihara
Takeshi Shimamoto Department of Cardiovascular Surgery, Hamamatsu Rosai Hospital, Hamamatsu
Chairpersons' Message
With the aging of patients with aortic stenosis, narrow valve rings become a clinical problem. Implantation of a small biological valve for a patient's physique results in a patient-prosthetic-mismatch (PPM), creating the dilemma that stenosis remains postoperatively despite treatment for stenosis. Long-term results after AVR with PPM is proved to be poor, and annular enlargement may be applied to avoid it. On the other hand, there are some reports that PPM is not clinically problematic even if a 19 mm or 21 mm biological valve is implanted in Japanese people of small physique, and there is an honest desire to avoid annular enlargement as much as possible because it involves the risk of bleeding from the aortic base, so the indication of aortic annular enlargement is still controversial. Recently, the choice of artificial valves for people in their 60s and 50s has been the subject of debate due to the expansion of indications for low-risk and for non-elderly people TAVR indications, and the combination of artificial valve options from the perspective of whole life span is an issue. Of course, the mechanical valve at the first time is also an option. When a biological valve is selected, and subsequent TAVR in SAVR or TAVR in TAVR in SAVR are considered, it is necessary to implant a biological valve as large as possible at the time of the initial surgery. So the expansion of the aortic valve annulus becomes an attracting attention again. We would like to discuss the current indication of the expansion of the aortic annulus and the selection strategy of the artificial valve considering the whole life span for young people.

English

Symposium 10

March 9 (Sat), 2024 08:00-09:30 Room 1 Kobe Portopia Hotel 1F Portopia Hall

SY10
Current and Future Status of Dyslipidemia Treatment for Prevention of Atherosclerotic Disease
Chairpersons: Koh Ono Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine
Diane Brisson Department of Médicine, Universite de Montreal, Canada
Keynote Lecture:
Diane Brisson Department of Médicine, Universite de Montreal, Canada
Speaker: Hirotaka Fukami Department of Molecular Genetics, Graduate School of Medical Sciences, Kumamoto University, Kumamoto
Takahiro Horie Department of Cardiovascular Medicine, Kyoto
Kazuma Oyama Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai
Nobuko Kojima Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, Kanazawa
Chairpersons' Message
In our super-aging society, dyslipidemia is a major factor in the development and progression of arteriosclerotic diseases that threaten life expectancy and healthy longevity. Many clinical studies have shown the importance of lowering blood LDL cholesterol levels as much as possible as a treatment for dyslipidemia from the viewpoint of preventing the onset and recurrence of atherosclerosis. For this purpose, statins (HMG-CoA reductase inhibitors) are widely used in general and their efficacy has been established. In severe cases, treatment by increasing the dose of statins or adding other drugs (multiple-drug combination therapy) is used to lower blood LDL cholesterol levels as much as possible, but these treatments can cause adverse symptoms and abnormal laboratory values that make it difficult to continue treatment. Therefore, the development of new therapeutic agents is expected. Among them are nucleic acid drugs in the field of cardiovascular diseases and vaccine therapies that have been developed in recent years.
In addition, primary dyslipidemia showing abnormalities other than LDL cholesterol (primary hyperchylomicronemia, lecithin cholesterol acyltransferase (LCAT) deficiency, Tangier disease, sitosterolemia, cerebrotendinous xanthomatosis, and abetalipoproteinemia), studies have identified causative genes and clarified the pathophysiology of many of these diseases. We would like to discuss these primary dyslipidemias that we should keep in mind.

English

Symposium 11

March 9 (Sat), 2024 08:00-09:30 Room 6 Kobe Portopia Hotel South Building B1F Topaz

SY11
Management and Treatment of Adult Congenital Heart Disease Complicated with Pulmonary Artery Hypertension
Chairpersons: Teiji Akagi Department of Cardiovascular Medicine
Margarita Brida Medical Faculty University of Rijeka, Croatia and Royal Brompton Hospital, UK
Keynote Lecture:
Margarita Brida Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, UK, United Kingdom
Speaker: Hideo Ohuchi Adult Congenital Heart Disease Center, Suita
Teppei Fujita Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara
Takamori Kakino Department of Cardiovascular Medicine, Faculty of Medical Sciences, Fukuoka, Japan, Fukuoka
Satoshi Akagi Department of Cardiovascular Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama
Chairpersons' Message
Pulmonary artery hypertension (PAH) is observed in approximately 5% of adult congenital heart disease (ACHD) and represents a significant prognostic factor in this population. The condition can be categorized into four major clinical subgroups: Eisenmenger syndrome, PAH with large (persistent) shunts, PAH with small defects/accidental shunts, and post-repair PAH, each presenting distinct clinical characteristics. The prognosis of PAH has significantly improved with the introduction of various pulmonary vasoactive medications, which have also impacted the management of ACHD. The treatment landscape has expanded not only in terms of available pulmonary vasoactive medications but also in the utilization of these medications. Instead of conventional goal‒oriented sequential combination therapy, recent studies have reported that upfront combination therapy during the initial phase yields notable improvements in hemodynamics and prognosis. This therapeutic approach, so called “Treat and Repair” strategy, combines PAH medication with catheter or surgical interventions, promoted the potential to revolutionize the long-term outcomes of ACHD patients. complicated with PAH. In addition, Fontan circulation, which does not exactly fulfill the criteria for PAH, but in patients with increased pulmonary vascular resistance and for whom pulmonary vasoactive medications are clinically indicated, is considered a major area of discussion in this field. We would like to discuss the latest information on the management and treatment of ACHD complicated with PAH, utilizing knowledge in Japan, a world leader in the treatment of pulmonary hypertension.

Japanese

Symposium 12

March 9 (Sat), 2024 10:30-12:00 Room 6 Kobe Portopia Hotel South Building B1F Topaz

SY12
How has COVID-19 Affected Cardiovascular Medicine?
Chairpersons: Koichi Node Department of Cardiovascular Medicine, Saga University, Saga
Chisa Matsumoto Center for Health Surveillance & Preventive Medicine, Department of Cardiology, Tokyo Medical University, Tokyo
Speaker: Yutaka Furukawa Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe
Tomoo Nagai Division of Cardiology, Department of Internal Medicine, Tokai University School of Medicine, Isehara
Kunio Yufu Department of Cardiology and Clinical Examination, Faculty of Medicine, Oita University, Yufu
Hiroki Nakano Department of Cardiology, Tokyo Medical University, Tokyo
Hiraku Kumamaru Department of Healthcare Quality Assessment, Tokyo
Reiji Goto Aichi Medical University, Department of cardiology , Nagakute
Chairpersons' Message
It is evident that cardiovascular disease (CVD) is not only a poor prognostic factor for COVID-19; conversely, SARS-CoV-2 infection can directly or indirectly damage the cardiovascular system and induce CVDs. Furthermore, it is increasingly recognized that COVID-19 is associated not only with cardiovascular events in the acute phase, but also with cardiovascular dysfunction and an increased risk of CVDs in the chronic phase.
COVID-19 not only affects the pathophysiology of CVDs, but also has an impact on the cardiovascular care system. In Japan, it has been reported that emergency hospitalizations for CVD, as well as scheduled hospitalizations and elective surgeries, decreased in association with the COVID-19 pandemic. It has also been suggested that acute cardiovascular care may have been overwhelmed not only because of the reduction of hospital beds and medical resources due to the COVID-19 pandemic, but also due to the clusters in core community hospitals and the infection and close contact of healthcare workers. In addition, the chronic care system may have been affected by the long-term care hospital and cardiac rehabilitation, which is a key component of the chronic care system.
Furthermore, it is conjectured that COVID-19 affects cardiovascular care not only on the provider side but also on the patient side, such as manifesting in behaviors such as avoidance of medical services. Moreover, changes in physical activity and dietary habits might further influence the chronic phase and prevention of cardiovascular diseases.
On the other hand, the COVID-19 pandemic has stimulated the digital transformation of healthcare (Dx), including online medical services, and has brought into sharp relief the issues of equalization, centralization, and regional collaboration in the conventional cardiovascular care system.
In this symposium, we comprehensively examine the impact of COVID-19 on cardiovascular medicine from various perspectives and discuss the future of cardiovascular care in the face of exigent circumstances such as a pandemic resurgence.

Japanese

Symposium 13

March 9 (Sat), 2024 13:30-15:00 Room 3 Kobe Portopia Hotel South Building 1F Ohwada B

SY13
If you were a Man or Woman Working as a Cardiologist, What would you do? -Open Debate
Chairpersons: Hideki Ishii Department of Cardiovascular Medicine Gunma University Graduate School of Medicine, Maebashi
Atsuko Nakayama Department of Cardiology, Sakakibara Heart Institute, Tokyo
Speaker: Norimichi Koitabashi Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine, Maebashi
Sachiko Kanki Department of Thoracic and Cardiovascular Surgery, Osaka Medical and Pharmaceutical University, Takatsuki
Ayako Harima Toranomon Hospital, Tokyo
Yoshihiro Akashi Department of Cardiology, St. Marianna University School of Medicine, Kawasaki
Tsugumi Takayama Department of Cardiovascular Medicine, Niigata University, Niigata
Yugo Yamashita Graduate School of Medicine, Kyoto University, Kyoto
Mai Shimbo Department of Cardiovascular Medicine, The University of Tokyo, Tokyo

English

Symposium 14

March 9 (Sat), 2024 13:30-15:00 Room 6 Kobe Portopia Hotel South Building B1F Topaz

SY14
Cardiovascular Disease and Aging/Immunity
Chairpersons: Tohru Minamino Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo
Niels P. Riksen Internal Medicine, Radboud university medical center, The Netherlands
Keynote Lecture:
Niels P. Riksen Internal Medicine, Radboud university medical center, The Netherlands
Speaker: Yoshikazu Nakaoka Department of Vascular Physiology,, National Cerebral and Cardiovascular Center Research Institute, Suita
Takuo Emoto Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe
Masataka Yokoyama Department of Molecular Diagnosis, Chiba
Goro Katsuumi Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo
Chairpersons' Message
Aging is the greatest risk factor for most metabolic and cardiovascular diseases, such as atherosclerosis, heart failure, and diabetes. Therefore, elucidating the mechanisms of age-related development and progression of metabolic and cardiovascular diseases is expected to lead to the development of new therapeutic strategies. Inflammation induced by aging is assumed to be involved in the onset and progression of various age-related diseases, including metabolic and cardiovascular diseases. It has been suggested that clonal blood cell proliferation, abnormal intestinal microflora, accumulation of senescent cells, and abnormal immune system responses are involved in the mechanism of chronic inflammation induced by aging. For example, mutations in molecules involved in age-related epigenomic modifications have been shown to induce clonal hematopoiesis and to be involved in atherosclerosis, heart failure, and chronic thromboembolic pulmonary hypertension via chronic inflammation. Age-associated changes in the intestinal microbiota induce a disruption of the intestinal barrier and associated systemic chronic inflammation. It has also become clear that senescent cells accumulate due to genomic stresses that increase with aging, and the inflammatory molecules they secrete induce chronic inflammation and organ aging. These studies have led to the development of epigenome-targeted therapies, therapies aiming at the normalization of intestinal bacteria, and therapies by removing senescent cells, respectively. In this session, we will discuss the current status and future prospects of metabolic and cardiovascular disease control by age-related chronic inflammation, which will lead to the development of new therapeutic strategies for metabolic and cardiovascular diseases that increase with age.

Japanese

Symposium 15

March 10 (Sun), 2024 08:00-09:30 Room 1 Kobe Portopia Hotel 1F Portopia Hall

SY15
Future of Cardiovascular Imaging with Artificial Intelligence
Chairpersons: Shiro Uemura Department of Cardiology, Kawasaki Medical School, Kurashiki
Masahiro Jinzaki Department of Radiology, Keio University School of Medicine, Tokyo
Speaker: Nobuyuki Kagiyama Department of Cardiovascular Biology and Medicine, Juntendo University, Tokyo
Rine Nakanishi Division of Cardiovascular Medicine, Department of Internal Medicine Toho University Faculty of Medicine, Toho University Omori Medical Center, Tokyo
Risako Nakao Department of Cardiology, Tokyo Women's Medical University, Tokyo
Shuichiro Kaji Department of Cardiovascular Medicine, Kansai Electric Power Hospital, Osaka
Yu Nishihara Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe
Chairpersons' Message

AI (artificial intelligence) has the potential to provoke revolutionary changes in the field of healthcare. In cardiovascular medicine, AI-based comprehensive analysis of patient information, including images, contributes not only to accurate diagnosis but also to stratifying optimal patient management. Furthermore, tremendous medical resources and manpower are spent on an accurate diagnosis of medical imaging in the current practice of cardiovascular medical care. The AI-based automated diagnosis is expected to greatly contribute to reducing the burden not only on patients but also on medical personnel and medical facilities.

At this symposium, experts give lectures on AI in the field of cardiovascular imaging, including current status and problems to be solved, and the future perspectives for cardiovascular medical care in the near future.

Japanese

Symposium 16

March 10 (Sun), 2024 08:00-09:30 Room 3 Kobe Portopia Hotel South Building 1F Ohwada B

SY16
How Multimodality Imaging Guides Decision Making in Management of Valvular Heart Diseases
Chairpersons: Tatsuhiko Komiya Department of Cardiovascular Surgery, Tatsuhiko Komiya, Kurashiki
Chisato Izumi Department of Heart Failure and Transplantation, National Cerebral and Cardiovascular, Suita
Speaker: Ai Kawamura Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita
Takahide Yoshio Department of cardiovascular urgery, International University of Health and Welfare Mita Hospital, Tokyo
Hiroyuki Iwano Division of Cardiology, Teine Keijinkai Hospital, Sapporo
Hideaki Kanzaki Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita
Haruka Sasaki Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba
Masao Daimon Department of Cardiology, International University of Health and Welfare, Mita Hospital, Tokyo
Chairpersons' Message
Patients with valvular heart diseases (VHD) has been increasing with aging society. Treatment strategy for VHD has dramatically changed after the introduction of transcatheter treatments for aortic stenosis and mitral regurgitation. Surgical treatment has also progressed, including minimally invasive surgery and valve sparing surgery for aortic regurgitation.
In order to picture the best scenario for each patient with VHD, we should accurately evaluate severity of VHD, morphology of valve complex, and the degree of myocardial damage, and its importance has increased as we have more choices for treatment.
Echocardiography is the center of diagnostic tools of VHD, because it can evaluate all aspects of VHD as mentioned above. In addition, cardiac CT scan is useful to evaluate the degree and distribution of valve calcification, aortic root and coronary arteries, as well as cardiac MRI can evaluate myocardial damage and quantification of regurgitation.
In this session, we will discuss how the multimodality imaging can be utilized for choosing best strategy for patients with VHD in the era of multimodality imaging.

Japanese

Symposium 17

March 10 (Sun), 2024 08:00-09:30 Room 6 Kobe Portopia Hotel South Building B1F Topaz

SY17
Work-style Reform of Medical Doctors - How Should We Do?
Chairpersons: Yoshio Kobayashi Department of Cardiovascular Medicine, Chiba University
Hiroyuki Watanabe Department of Cardiovascular Medicine, Akita University, Akita
Speaker: Masato Kanda Department of Cardiology, Chiba University Graduate School of Medicine, Chiba
Motoki Nakao Department of Cardiovascular Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo
Keita Inoguchi Department of Cariovascular Surgery, Osaka University, Suita
Manabu Kurabayashi Division of Cardiology, Yokohama CIty Minato Red Cross Hospital, Yokohama
Junjiroh Koyama Division of cardiology, Saiseikai Kumamoto Hospital, Cardiovascular Center, Kumamoto
Norihiko Shinozaki Department of Cardiology, Asama General Hospital, Saku
Chairpersons' Message
The work-style reform of medical doctors will start in April, 2024. The overwork of medical doctors has been recognized, but there has been no solution. It is the first step, although the limit of overwork time is 1,860 hours, which is still overwork. There are many problems to do the work-style reform. There may be a risk of medical collapse. Japan is the one of the countries with the lowest mortality rate for acute myocardial infarction in the world. It may be because many Japanese hospitals perform primary percutaneous coronary intervention in patients with acute myocardial infarction even at night. In other words, many cardiologists work even at night. In this work-style reform, the doctors who have the limit of overwork time of 1,860 hours cannot work the next day, if they work at night, because it requires the mandatory rest between work. They cannot take care of inpatients and outpatients the next day they work at night. In this situation, some hospitals may stop receiving emergency patients at night. There are other problems related with this work-style reform. In this symposium, the presenters will show their measures for the work-style reform and discuss how we should do.

English

Symposium 18

March 10 (Sun), 2024 08:00-09:30 Room 10 Kobe International Exhibition Hall No.1 Building 2F Exhibition Hall B

SY18
Future Prospects of Registries and Data Banks in Cardiovascular Disease in Japan
Chairpersons: Satoshi Yasuda Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai
Paul M. Matthews Department of Brain Sciences and UK Dementia Research Institute at Imperial College, London, UK
Keynote Lecture:
Paul M. Matthews Department of Brain Sciences and UK Dementia Research Institute at Imperial College, London, UK
Speaker: Nobuhiko Ueda Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita
Yuichi Tamura Department of Cardiology, International University of Health and Welfare School of Medicine, Tokyo
Takashi Shiroto Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai
Tetsuya Matoba Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka
Chairpersons' Message
Evidence-based medicine (EBM) relies on high-quality research findings from randomized controlled trials (RCTs). RCTs minimize bias, but there are "5 Too" limitations. In real-world clinical practice, diverse patients excluded from RCTs are often treated. Registry studies complement RCT limitations, aid hypothesis construction, and predict disease progression. Analyzing gene and protein expression in disease processes and clarifying molecular targets and pathways through genome omics research is crucial. Future prospects of registry and biobank studies will be discussed in this session.

Japanese

Symposium 19

March 10 (Sun), 2024 08:00-09:30 Room 16 Kobe International Conference Center 1F Main Hall

SY19
Medical System for Acute Aortic Dissection
Chairpersons: Morimasa Takayama Department of Cardiology, Sakakibara Heart Institute, Tokyo
Yoshikatsu Saiki Division of Cardiovascular Surgery, Tohoku University
Speaker: Hiroshi Imamura Department of Emergency and Critical Care Medicine, Shinshu University, Matsumoto
So Izumi Division of Cardiovascular Surgery, Japanese Red Cross Kobe Hospital and Hyogo Emergency Medical Center, Kobe
Kota Itagaki Division of Cardiovascular Surgery, Tohoku University Hospital, Sendai
Kazuo Shimamura Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita
Toshiyuki Takahashi Tokyo CCU Network Scientific Committee, Tokyo
Chairpersons' Message
Acute aortic dissection represents a catastrophic entity evoking severe dreadful pain with sudden onset among people in their prime. The incidence of acute aortic dissection accounts for 1,600 cases a year in Tokyo, and it reaches 2,000 cases when ruptured degenerative aortic aneurysms are included as acute aortic syndrome. When it occurs in its most severe form, such as cardiopulmonary arrest on admission to the emergency department, it is thought to carry approximately 20% of in-hospital mortality rate that exceeds the mortality rate of acute myocardial infarction. While the importance of elucidation of pathophysiology involved in acute aortic dissection is indisputable, the key to saving those patients from crush in hemodynamics, where every second counts, lies in the efforts encompassing the entire aspects of emergency medicine. In addition to cardiovascular emergency medicine, the close collaboration sustaining 24 hours between cardiology, cardiovascular surgery, anesthesiology, intensive care, radiology, nursing, and clinical engineering departments can save numerous lives. Accurate and precise diagnostic imaging and its remote transmission are required for prompt diagnosis on cases indicated for emergent surgical management. The establishment of a cooperative system for secondary and tertiary emergency medical services in the region also requires close cooperation beyond the boundaries of specialized departments, and this can only be achieved with the support of the regional government for organization and its operation. There remain multiple unsolved issues toward the establishment of emergent diagnosis and treatment strategies to achieve our goal to overcome this disease. With an estimated 20,000 cases and thousands of deaths each year to be reckoned with in Japan, it is time for the entire medical community to make a strong shift toward a solution to this challenging disease, with the aid of "Basic Plan for the Promotion of Cardiovascular Disease Control" set by the Ministry of Health, Labor and Welfare and local governments as a force. We would like to create an opportunity for meaningful discussion by soliciting many advanced and practical achievements and initiatives.

English

Symposium 20

March 10 (Sun), 2024 10:30-11:50 Room 3 Kobe Portopia Hotel South Building 1F Ohwada B

SY20
Impact of Impella on Post-cardiotomy Cardiogenic Shock
Chairpersons: Hiroshi Niinami Department of Cardiovascular Surgery, Tokyo Women's Medical University, Tokyo
Koichi Toda Department of Cardiovascular Surgery, Dokkyo Medical University Saitama Medical Center
Speaker: Hirotaka Yamauchi Department of Cardiovascular Surgery, Nagoya Tokushukai General Hospital, Japan, Nagoya
Yuki Ichihara Department of Cardiovascular Surgery, Tokyo Women's Medical University, Tokyo
Tomoki Ushijima Department of Cardiovascular Surgery, Kyushu University Hospital, Fukuoka
Keitaro Domae Department of Cardiovascular Surgery, Osaka Police Hospital, Osaka
Senri Miwa Department of Cardiovascular Surgery, Okamura Memorial Hospital, Shimizu cho, Shizuoka Pref.
Takuji Kawamura Department Cardiovascular Surgery, Osaka University Graduate School of Medicine , Suita
Chairpersons' Message
Impella is a microaxial blood pump catheter, which could be placed in left ventricle (LV) from peripheral arteries and unload the LV by ejecting the blood from LV to the ascending aorta. It has been used as a less invasive LV assist device in more than 8000 patients with cardiogenic shock in the last 5 and a half years since its approval in Japan. The analysis of Japan Registry for Percutaneous Ventricular Assist Device (J-PVAD) demonstrated its clinical benefits in shock patients due to acute myocardial infarction or fulminant myocarditis. In this symposium we focus on the impact of Impella in patients who suffer from post-cardiotomy cardiogenic shock (PCC) and try to answer to the important clinical questions including ① Benefit of left ventricular unloading in PCC, ② Impact of Impella device on coagulopathy after cardiac surgery, ③ Impact of left ventricular unloading on coronary collateral flow in CABG for acute or chronic ischemia. I hope that this symposium will shed light on the benefit of left ventricular unloading in post-cardiotomy cardiogenic shock (PCC).

Japanese

Symposium 21

March 10 (Sun), 2024 13:20-14:50 Room 5 Kobe Portopia Hotel South Building B1F Sapphire

SY21
Indications for BTT and DT; Similarities and Differences
Chairpersons: Minoru Ono Department of Cardiovascular Surgery, , The University of Tokyo, Tokyo
Osamu Yamaguchi Department of Cardiology, Pulmonology, Hypertension and Nephrology, Ehime University Graduate School of Medicine
Speaker: Koichiro Kinugawa The Second Department of Internal Medicine, University of Toyama, Toyama
Toru Miyoshi Department of Cardiology, Pulmonology, Hypertension and Nephrology. Ehime Graduate School of Medicine, Toon
Ayumi Goda Department of Cardiovascular Medicine, Tokyo
Noriko Kikuchi Department of Cardiology, Tokyo Women's Medical University, Shinjuku-ku
Yasumasa Tsukamoto Department of Transplant Medicine, National Cerebral and Cardiovascular Center, Suita
Eisuke Amiya Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, The University of Tokyo, Tokyo
Chairpersons' Message
Implantation of ventricular assist device are classified into BTT (Bridge to Transplantation) and DT (Destination Therapy: long-term home use assisted artificial heart therapy) based on their primary goal. In Japan, only VAD implantation as BTT had been reimbursed by insurance, but on April 30, 2021, DT using HeartMate3 was covered by insurance and started at 7 institutions. In July 2023, DT was expanded to 19 facilities, and transfer to distant medical facilities for DT could be avoided in many areas. However, it is not possible to completely classify VAD treatment into BTT and DT. In the past, BTT at the age of 60-65 years has been recognized as a condition similar to DT due to the practical difficulty in reaching heart transplantation, and the waiting period for pure BTT is well over 5 years. In addition, the indication for DT itself is not far removed from the indication for heart transplantation. It is important to have a thorough knowledge of the conditions and indications for heart transplantation in order to understand DT.

Japanese

Symposium 22

March 10 (Sun), 2024 13:20-14:50 Room 9 Kobe International Exhibition Hall No.1 Building 2F Exhibition Hall A

SY22
Diagnosis and Treatment of Arrhythmia - Role of AI
Chairpersons: Eiichi Watanabe Division of Cardiology, Department of Internal Medicine, Fujita Health University Bantane Hospital,
Tetsuo Sasano Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo
Speaker: Shuhei Toba Department of Thoracic and Cardiovascular Surgery, Mie University Graduate School of Medicine, Tsu
Tomofumi Nakamura Department of Cardiology, Nagoya Heart Center, Nagoya
Yuichi Tamura Department of Cardiology, International University of Health and Welfare Mita Hospital, Tokyo
Eriko Hasumi Department of Cardiology, The university of Tokyo hospital, Tokyo
Takashi Noda Department of Cardiology, Tohoku University Hospital, Sendai
Chairpersons' Message
In recent years, the utilization of artificial intelligence (AI) models in the diagnosis of arrhythmias has achieved remarkable success. One prominent example is the use of AI for electrocardiogram (ECG) analysis, which is employed to support risk stratification, including the cardiac function evaluation, identification of ischemic changes, and prediction of sudden cardiac death and atrial fibrillation. The use of AI extends beyond the standard 12-lead ECG and can be applied to various types of ECGs, such as Holter ECGs and ECGs obtained from wearable devices, enabling improvements in the accuracy of automated diagnosis and the establishment of new risk assessment methods.
The utilization of AI in arrhythmia management involves not only the conventional approach of applying various learning models to ECGs as chronological data or image data but also the integration of other information, including text data, to create multimodal models. The rapid progress of AI models, particularly large-scale language models, holds significant potential in advancing this field. Research utilizing large-scale language models in generating AI, such as ChatGPT (Generative Pre-trained Transformer), and applying them to text-based medical record suggests the possibility of these models performing expert-level diagnoses. These multimodal AI models expands the application of AI for the treatment of arrhythmia from conventional black-box AI to explainable AI that reflects medical reasoning.
In this symposium, we will discuss the progress regarding the development and implementation of AI models for ECG interpretation in clinical settings. Additionally, we will explore the application of AI in arrhythmia management using other data sources.

Japanese

Symposium 23

March 10 (Sun), 2024 15:30-17:00 Room 2 Kobe Portopia Hotel South Building 1F Ohwada A

SY23
JSMO-JCS Joint Symposium 2024: Management of Cancer Therapy-Related Cardiovascular Toxicity - Onco-Cardiology Clinical Practice Guidelines
Chairpersons: Kazuhiro Sase Clinical Pharmacology and Regulatory Science, Graduate School of Medicine, Juntendo University, TOKYO
Shingo Yano Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo
Speaker: Hirotsugu Yamada Department of Coomunity Medicine for Cradiology, Tokushima
Yuichi Tamura Department of Cardiology, International University of Health and Welfare Mita Hospital, Tokyo
Yutaka Furukawa Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe
Masataka Sawaki Department of Breast Oncology, Nagoya
Nobuhiko Yamauchi Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo
Chairpersons' Message

Title: "JSMO-JCS Joint Symposium 2024: Management of Cancer Therapy-Related Cardiovascular Toxicity - Onco-Cardiology Clinical Practice Guidelines."

The Japanese Society of Clinical Oncology (JSMO) and the Japanese Circulation Society (JCS) are pleased to announce the 2024 Joint Symposium on "Management of Cancer Therapy-Related Cardiovascular Toxicity." This event highlights the importance of interdisciplinary collaboration to tackle emerging cardiovascular challenges in cancer patients.

Since 2016, JSMO and JCS have advanced collaborations leading to the establishment of the Japanese Onco-Cardiology Society (JOCS), the publication of the Onco-Cardiology Handbook, and most recently, the Onco-Cardiology Clinical Practice Guidelines.

These latest guidelines are a major milestone in our interdisciplinary initiative. They are systematically designed to align with real-world clinical practice, providing robust, evidence-based approaches for managing cancer patients' cardiovascular health. The guidelines were developed following the Medical Information Network Distribution Service (MINDS) process, with input from experts across relevant societies, reinforcing their comprehensiveness and relevance.

The JSMO-JCS joint session at JCS2024 will focus on these guidelines, exploring their implications and applications in various clinical contexts such as "Cancer Pharmacotherapy and Echocardiography (GLS)," "Immune Checkpoint Inhibitors and Myocarditis," and "Cardiovascular Complications of Anti-HER2 Therapies for Brest Cancer Patients."

Our goal with this joint symposium is to amplify the reach and application of the Onco-Cardiology Clinical Practice Guidelines, thereby fostering education, enhancing clinical practice, stimulating research to fill the evidence gaps, and ultimately improving patient outcomes.

Japanese

Symposium 24

March 10 (Sun), 2024 15:30-17:00 Room 5 Kobe Portopia Hotel South Building B1F Sapphire

SY24
Health Economic Evaluation (Cost-effectiveness Evaluation) in Cardiovascular Medicine
Chairpersons: Shin-ichiro Miura Department of Cardiology, Fukuoka University School of Medicine
Tomoyuki Takura Department of Healthcare Economics and Health Policy, Graduate School of Medicine, The University of Tokyo, Tokyo
Speaker: Tomoyuki Takura Department of Healthcare economics and Health policy, Graduate school of Medicine, The University of Tokyo, Tokyo
Hitoshi Uchinoumi Division of Cardiology, Department of Medicine and Clinical Science, Ube
Hiroshi Kawakami Division of Cardiology, Department of Cardiology, Pulmonology, Hypertension, and Nephrology, Ehime University Graduate School of Medicine, Toon
Satoshi Kodera Department of Cardiovascular Medicine, The University of Tokyo Hospital, Tokyo
Koichi Nakao Division of Cardiology, Saiseikai Kumamoto Hospital Cardiovascular Center, Kumamoto
Chairpersons' Message
Against the backdrop of an aging society and increasing demand for heart failure treatment, as well as the scars of emerging infectious diseases and the stagnation of the real economy, the universal health insurance system that supports circulatory system in Japan is approaching a major milestone. In 2024, the medical insurance and long-term care insurance reimbursement systems will be revised simultaneously, and there is a possibility that a certain degree of discussion will take place on the future of the medical insurance system, along with strengthening evidence-based discussions, expanding cost-effectiveness evaluation, promoting medical innovation, and promoting coordination of medical treatment functions. In light of these trends, we speculate that it is desirable to construct new medical treatment systems and management models in the field of circulatory system, with an eye to the Epidemiologic Transition and the increasing incidence of ischemic heart failure.
In this symposium, we will discuss the current status and future of circulatory system from the viewpoint of health economic value evaluation (cost-effectiveness evaluation), with the aim of sustainable development of this field, especially stable provision of medical care in the community, based on a future-oriented approach. For example, along with trends in cost-effectiveness evaluation of the latest pharmaceuticals and treatment materials, we would like to discuss the healthcare economics of critical illness prevention and team medicine, as well as healthcare management topics such as efforts to reform work styles. The content discussed in this session may provide clues to solutions to the exhaustion of clinical practice and the challenges of medical practice development, and we hope that it will contribute to the health economic development of this field.

Japanese

Symposium 25

March 10 (Sun), 2024 15:30-17:00 Room 6 Kobe Portopia Hotel South Building B1F Topaz

SY25
Beyond 5G: Transforming Cardiovascular Care
Chairpersons: Mitsuru Ohishi Department of Cardiovascular Medicine and Hypertension, Kagoshima University, Kagoshima
Kenya Kusunose Department of Cardiovascular Medicine, Nephrology, and Neurology, University of the Ryukyus, Okinawa
Speaker: Yuichiro Uchida Ministry of Internal Affairs and Communications, Tokyo
Oto Hiroyuki 6G Network Innovation Department, NTT DOCOMO, INC., Yokosuka
Katsuhiko Yokota Department of Emergency and Disaster Medicine, Nishinomiya
Jin Komuro Department of Cardiovascular Medicine, The University of Tokyo, Tokyo
Masataka Sato The University of Tokyo Hospital, Tokyo
Chairpersons' Message
The spread of 5G communication technology has made it possible for us to send large amounts of data at high speeds, bringing innovative changes to cardiovascular medicine. 5G technology make it possible that we have new possibilities in the medical field, such as remote medical care, real-time large data transmission, and AI-supported diagnosis. In the field of cardiovascular medicine, the use of various data analyses for early disease detection, AI-based image diagnosis, remote medical care, and other potential applications of 5G are expected to greatly improve the quality and speed of diagnosis. Our next goal is to explore the future of medicine through technological innovations beyond 5G. By thinking about cardiovascular treatment from the perspective of digital transformation, beyond the traditional framework of medicine, we may create a new connection between individual patients and medical care. However, there are many new challenges in utilizing these advanced technologies, such as social ethical issues, delays in legal development, and the control of evolving AI. For these issues, it is necessary to multidimensional discussions that include the perspectives of businesses and government regulators. In this session, we want to stimulate discussions not only about the current changes in cardiovascular medicine brought about by 5G, but also about the future of cardiovascular medicine beyond 5G.

Special Session

Japanese

Special Session 1

March 8 (Fri), 2024 08:00-09:30 Room 6 Kobe Portopia Hotel South Building B1F Topaz

SS1
Clonal hematopoiesis In cardiovascular diseases
Chairpersons: Toshio Kitamura Institute of Biomedical Research and Innovation, Foundation for Biomedical Research and Innovation at Kobe, Kobe
Tomoya Yamashita Division og Advanced Medical Science, Kobe University Graduate School of Science, Technology and Innovation , Kobe
Speaker: Toshio Kitamura Institute of Biomedical Research and Innovation, Foundation for Biomedical Research and Innovation at Kobe, Kobe
Yoshimitsu Yura Department of Cardiology, Nagoya University School of Medicine, Nagoya
Soichi Sano Laboratory of Cardiovascular Mosaicism, Suita
Tomofumi Misaka Department of Cardiovascular Medicine, Fukushima Medical University, Fukushima

English

Special Session 2

March 8 (Fri), 2024 08:00-09:30 Room 8 Kobe Portopia Hotel South Building B1F Ruby

SS2
How to Treat Femoropopliteal Severe Calcified Lesion
Chairpersons: Kazushi Urasawa Department of Cardiovascular Medicine, Tokeidai Memorial Hospital, Sapporo
Yusuke Miyashita Department of Cardiology, Nagano Red Cross Hospital, Nagano
Speaker: Sho Torii Department of Cardiology, Tokai University School of Medicine, Isehara
Amane Kozuki Division of Cardiology, Osaka Saiseikai Nakatsu Hospital, Osaka
Michinao Tan Department of Cardiology, Tokeidai Memorial Hospital, Sapporo
Masahiko Fujihara Department of cardiology, Kishiwada Tokushukai Hospital, Kishiwada
Yoshimitsu Soga Department of Cardiology, Kokura Memorial Hospsital, Kitakyushu
Osamu Iida Osaka Police Hospital, Osaka

Japanese

Special Session 4

March 8 (Fri), 2024 09:30-10:45 Room 5 Kobe Portopia Hotel South Building B1F Sapphire

SS4
Unveiling the mythtery of coronary artery disease -pathology and imaging-
Chairpersons: Takashi Akasaka Department of Cardiovascular medicine, Nishinomiya Watanabe Cardiovascular Cerebral Center, Hyogo/Japan
Shiro Uemura Department of Cardiology, Kawasaki Medical School, Kurashiki
Speaker: Gaku Nakazawa Kindai University Faculty of Medicine, Osakasayama
Fumiyuki Otsuka Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita
Takuo Emoto Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe

English

Special Session 5

March 8 (Fri), 2024 09:30-11:00 Room 9 Kobe International Exhibition Hall No.1 Building 2F Exhibition Hall A

SS5
Current status and Topics of ACHD Catheter Interventions
Chairpersons: Mario Carminati Pediatric and Adult Congenital Cardiology, IRCCS Policlinico San Donato, Italy
Terunobu Fukuda Kobe University, Kobe
Speaker: Mario Carminati Pediatric and Adult Congenital Cardiology, IRCCS Policlinico San Donato, Italy
Tomohito Kogure Department of Cardiology, Tokyo Women's Medical University, Tokyo
Kazuto Fujimoto Department of Pediatric Cardiology, National Cerebral and Cardiovascular Center, Suita
Takashi Miki Department of Cardiovascular Medicine, Okayama University Hospital, Okayama
Toshikatsu Tanaka Department of Cardiology, Kobe Children's Hospital, Kobe

English

Special Session 6

March 8 (Fri), 2024 13:30-15:00 Room 3 Kobe Portopia Hotel South Building 1F Ohwada B

SS6
Novel Findings in Aortic Aneurysm and Dissection
Chairpersons: Clinton Robbins Toronto General Research Institute, University of Toronto, Canada
Hiroki Aoki Cardiovascular Research Institute, Kurume University, Kurume
Speaker: Clinton Robbins Toronto General Research Institute, University of Toronto, Canada
Hiromi Yanagisawa Life Science Center for Survival Dynamics, TARA, Tsukuba
Hisashi Sawada Saha Cardiovascular Research Center, University of Kentucky, United States of America
Hiroki Aoki Cardiovascular Research Institute, Kurume University, Kurume

Japanese

Special Session 8

March 8 (Fri), 2024 16:25-17:55 Room 6 Kobe Portopia Hotel South Building B1F Topaz

SS8
Advances in valvular heart disease treatment based on the latest imaging
Chairpersons: Shuichiro Takanashi Department of Cardiacvascular Surgery, Kawasaki Saiwai Hospital, Kanagawa
Hidekazu Tanaka Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe
Speaker: Tatsuhiko Komiya Depatment of Cardiovascular Surgery, Kurashiki Central Hospital, Kurashiki
Shumpei Mori Cardiac Arrhythmia Center, UCLA , USA
Takashi Kunihara Department of Cardiac Surgery, The Jikei University School of Medicine, Tokyo
Nozomi Watanabe Cardiovascular Physiology, University of Miyazaki Faculty of Medicine, Miyazaki
Hiroaki Takahashi Department of Cardiovascular Surgery, Kobe University Graduate school of Medicine, Kobe
Takashi Miura Department of Cardiovascular Surgery, Nagasaki city

English

Special Session 9

March 9 (Sat), 2024 08:00-09:30 Room 4 Kobe Portopia Hotel South Building 1F Ohwada C

SS9
Evolution of PAH management over the next decade
Chairpersons: Hiromi Matsubara Cardiology, NHO Okayama Medical Center, Okayama
Yuichi Tamura Department of Cardiology, International University of Health and Welfare School of Medicine, Tokyo
Discussant:
Shiro Adachi Department of Cardiology, Nagoya University Hospital, Nagoya
Kimi Sato University of Tsukuba, Tsukuba
Speaker: Marc Humbert Respiratory Medicine, University Paris-Saclay, France
Hiromi Matsubara Department of Cardiology, NHO Okayama Medical Center, Okayama

Japanese

Special Session 11

March 9 (Sat), 2024 10:30-12:00 Room 8 Kobe Portopia Hotel South Building B1F Ruby

SS11
Surgical Treatment of Acute Aortic Dissection with Malperfusion：up-to date
Chairpersons: Kenji Minatoya Department of Cardiovascular Surgery, Kyoto University
Kenji Okada Division of Cardiovascular Surgery, Kobe University, Kobe
Speaker: Yosuke Inoue National Cerebral and Cardiovascular Center, Suita
Masatoshi Koga National Cerebral and Cardiovascular Center, Suita
Hiroaki Takahashi Department of Cardiovascular Surgery, Kobe University Graduate school of Medicine, Kobe
Keiji Uchida Cardiovascular Center, Yokohama City University Medical Center, Yokohama
Koji Kawahito Department of Cardiovascular Surgery, Jichi Medical University, Shimotsuke
Masato Yamaguchi Department of Diagnostic and Interventional Radiology, Kobe University Hospital, Kobe

English

Special Session 12

March 9 (Sat), 2024 16:25-17:55 Room 10 Kobe International Exhibition Hall No.1 Building 2F Exhibition Hall B

SS12
Heart failure: From Bench to Bedside
Chairpersons: Koichiro Kuwahara Department of Cardiovascular Medicine, Shinshu University School of Medicine, Matsumoto
Hidetaka Kioka Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita
Speaker: Toshiyuki Ko Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo
Masataka Ikeda Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka
Manabu Nagao Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe University, Kobe
Tomoya Kitani Department of Cardiovascular Medicine, Kyoto Prefectural University of Medicine, Kyoto
Taketaro Sadahiro Department of Cardiology, Institute of Medicine, University of Tsukuba, Tsukuba
Yohko Yoshida Department of Department of Advanced Senotherapeutics, Juntendo University Graduate School of Medicine, Tokyo

Japanese

Special Session 13

March 10 (Sun), 2024 08:00-09:30 Room 2 Kobe Portopia Hotel South Building 1F Ohwada A

SS13
Lifelong Lead Management in TLE Era
Chairpersons: Morio Shoda Department of Cardiology, Tokyo Women's Medical University, Tokyo
Takuo Tsurugi Department of Cardiology, Saiseikai Kumamoto Hospital Cardiovascular Center, Kumamoto
Speaker: Hironori Matsuhisa Department of Cardiovascular Surgery, Kobe Children's Hospital, Kobe
Masahiko Goya International University of Health and Walfare Mita Hospital, Tokyo
Takashi Yamada Cardiovascular Center, Takaishi-Fujii Hospital, Takaishi
Katsuhide Hayashi Cleveland Clinic, USA

English

Special Session 14

March 10 (Sun), 2024 08:00-09:30 Room 9 Kobe International Exhibition Hall No.1 Building 2F Exhibition Hall A

SS14
Evolution of CTEPH management over the next decade
Chairpersons: Keiichi Ishida Department of Cardiovascular Surgery, Chibaken Saiseikai Narashino Hospital, Narashino city
Yu Taniguchi Department of Cardiology, Kobe University Hospital, Kobe
Speaker: Xavier Jais Université Paris-sud, Hôpital Bicêtre, France
Hiroto Shimokawahara NHO Okayama Medical Center, Department of Cardiology, Okayama
Yu Taniguchi Department of Cardiology, Kobe University Hospital, Kobe
Nobutaka Ikeda Division of Cardiovascular Medicine, Toho University Medical Center Ohashi Hospital, Tokyo
Takumi Inami Department of Cardiovascular Medicine, Kyorin University School of Medicine, Tokyo
Keiichi Ishida Chibaken Saiseikai Narashino Hospital, Narashino city

Japanese

Special Session 16

March 10 (Sun), 2024 10:30-12:00 Room 2 Kobe Portopia Hotel South Building 1F Ohwada A

SS16
Frontiers in cardiac CT
Chairpersons: Naoya Matsumoto Department of Cardiology, Nihon University Hospital, Tokyo
Tomofumi Takaya Department of Cardiovascular Medicine, Hyogo Prefectural Harima-Himeji General Medical Center, Himeji
Speaker: Seitaro Oda Department of Diagnostic Radiology, Kumamoto University Hospital, Kumamoto
Kakuya Kitagawa Department of Advanced Diagnostic Imaging, Mie University Graduate School of Medicine, Tsu
Makoto Nishimori Department of Molecular Epidemiology, Kobe University Graduate School of Medicine, Kobe
Kenichi Kurosaki Department of Pediatric Cardiology, National Cerebral and Cardiovascular Center, Suita, Osaka

Japanese

Special Session 17

March 10 (Sun), 2024 10:30-12:00 Room 15 Kobe International Exhibition Hall No.3 Building 1F Satellite Room

SS17
Chat GPT and Generative AI: Learn from experts about its usage and precautions!
Chairpersons: Nobuyuki Kagiyama Department of Cardiovascular Biology and Medicine, Juntendo University, Tokyo
Kenya Kusunose Department of Cardiovascular Medicine, Nephrology, and Neurology, University of the Ryukyus, Okinawa
Speaker: Nobuhiko Niida Cubec, Inc., Tokyo
Takeshi Kitamura Department of Cardiology, Ageo Central General Hospital, Saitama
Kenya Kusunose Department of Cardiovascular Medicine, Nephrology, and Neurology, University of the Ryukyus, Okinawa
Takuya Kishi Department of Graduate School of Medicine (Cardiology), International University of Health and Welfare, Okawa

Japanese

Special Session 20

March 10 (Sun), 2024 13:20-14:50 Room 15 Kobe International Exhibition Hall No.3 Building 1F Satellite Room

SS20
Gut Microbiota in Cardiovascular Diseases
Chairpersons: Yoshikazu Nakaoka Department of Vascular Physiology,, National Cerebral and Cardiovascular Center Research Institute, Suita
Tomoya Yamashita Division of Advanced Medical Science, Kobe University Graduate School of Science, Technology and Innovation , Kobe
Speaker: Tomoya Yamashita Division of Advanced Medical Science, Kobe
Eisaku Ito Sinyurigaoka general hospital, Kawasaki
Ryotaro Asano Department of Vascular Physiology, Suita
Yasushi Matsuzawa Kumamoto University Hospital, Kumamoto
Yoshikazu Nakaoka Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute, Suita

Japanese

Special Session 21

March 8 (Fri), 2024 09:30-11:00 Room 17 Kobe International Conference Center 3F International Conference Room

SS21
Japanese past, present, and future in the context of cardiovascular epidemiology research
Chairpersons: Shun Kohsaka Department of Cardiology, Keio University School of Medicine, Tokyo
Kunihiro Nishimura National Cerebral and Cardiovascular Center, Suita
Speaker: Yoshihiro Tanaka Graduate School of Public Health, Shizuoka Graduate University of Public Health, Shizuoka
Koshiro Kanaoka Department of Medical and Health Information Management, National Cerebral and Cardiovascular Center, Suita
Wataru Fujimoto Department of Cardiology, Hyogo Prefectural Awaji Medicine Center, Hyogo
Yuichiro Yano Department of General Medicine , Juntendo University Faculty of Medicine, Tokyo
Katsuyuki Miura NCD Epidemiology Research Center, Shiga University of Medical Science, Otsu

Japanese

Special Session 22

March 10 (Sun), 2024 15:30-17:00 Room 4 Kobe Portopia Hotel South Building 1F Ohwada C

SS22
Arrhythmia Treatment with X-rays and Particle Beams: Current Landscape, Future Prospects, and Advancing Toward Clinical Application in Japan
Chairpersons: Koichiro Yoshioka Department of Cardiology, Tokai university, Isehara
Tomoaki Okimoto Department of Radiology, Hyogo ion beam medical center, Tatsuno
Speaker: Tomoaki Okimoto Department of Radiology, Hyogo ion beam medical center, Tatsuno
Mitsuru Takami Section of Arrhythmia, Cardiovascular Division, Kobe University Graduate School of Medicine, Kobe
Mari Amino Department of Cardiology, Tokai University, Isehara
Koichiro Yoshioka Department of Cardiology, Tokai university, Isehara

English

Special Session 23

March 10 (Sun), 2024 15:30-16:30 Room 12 Kobe International Exhibition Hall No.2 Building 3F 3A Meeting Room

SS23
Circulation: Cardiovascular Imaging -Editor's Picks for 2023
Chairpersons: Robert J. Gropler Washington University of St. Louis; Editor-in-chief, Circulation: Cardiovascular Imaging
Nozomi Watanabe Cardiovascular Physiology, University of Miyazaki Faculty of Medicine, Miyazaki
Kazuaki Negishi University of Sydney; Section Editor (Digital Media Strategies), Circulation: Cardiovascular Imaging
Speaker: Robert J. Gropler Washington University of St. Louis; Editor-in-chief, Circulation: Cardiovascular Imaging
Nozomi Watanabe Cardiovascular Physiology, University of Miyazaki Faculty of Medicine, Miyazaki
Yasufumi Nagata University of Occupational and Environmental Health
Satoshi Kitahara Department of Cardiology, Kashiwa Kousei General Hospital, Kashiwa
Kazuaki Negishi University of Sydney; Section Editor (Digital Media Strategies), Circulation: Cardiovascular Imaging
Panelist: Yoshihiro Seo Department of Cardiology, Nagoya City University Graduate School of Medical Sciences, Nagoya
Masaru Obokata Department of Cardiovascular Medicine, Gunma University Hospital, Maebashi
Hiroto Utsunomiya Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima

Meet the Expert

English

Meet the Expert 1

March 8 (Fri), 2024 09:45-10:45 Room 4 Kobe Portopia Hotel South Building 1F Ohwada C

ME1
AV Node Unveiled: Emerging Discoveries in Anatomy, Physiology, and Electrophysiology
Chairpersons: Yoshiaki Kaneko Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine, Meabashi
Igor R. Efimov Northwestern University, USA
Speaker: Shumpei Mori Cardiac Arrhythmia Center, UCLA , USA
Igor R. Efimov Northwestern University, USA
Koichi Nagashima Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo

English

Meet the Expert 2

March 8 (Fri), 2024 13:30-15:00 Room 2 Kobe Portopia Hotel South Building 1F Ohwada A

ME2
How to utilize Echocardiography in the Era of the Heart Failure Pandemic?
Chairpersons: Patricia A. Pellikka Mayo Clinic; Journal of the American Society of Echocardiography, USA
Hidekazu Tanaka Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe
Speaker: Patricia A. Pellikka Mayo Clinic; Journal of the American Society of Echocardiography, USA
Masaru Obokata Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine, Maebashi
Hiroto Utsunomiya Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima
Hirotsugu Yamada Department of Community Medicine for Cardilogy, Tokushima University Graduate School of Biomedical Sciences, Tokushima
Hidekazu Tanaka Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe

English

Meet the Expert 3

March 9 (Sat), 2024 08:00-09:30 Room 2 Kobe Portopia Hotel South Building 1F Ohwada A

ME3
The Ventricular Arrhythmia arising from the Left Ventricular Summit; Anatomy, Mapping, Ethanol Ablation
Chairpersons: Hiroshi Tada Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui, Fukui
Yasuteru Yamauchi Department of Cardiology,, Japan Redcross Yokohama City Bay Hospital, Yokohama
Speaker: Shumpei Mori Cardiac Arrhythmia Center, UCLA , USA
Koji Fukuzawa Section of Arrhythmia, Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe
Miguel Valderrábano Houston Methodist Hospital, USA
Yuki Komatsu Department of Cardiology, University of Tsukuba, Tsukuba

Japanese

Meet the Expert 4

March 10 (Sun), 2024 08:00-09:30 Room 7 Kobe Portopia Hotel South Building B1F Emerald

ME4
Tips & Tricks for diagnosing secondary cardiomyopathy
Chairpersons: Hidekazu Tanaka Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe
Yasuhiro Izumiya Department of Cardiovascular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka
Speaker: Jin Endo Department of Cardiology, Keio University School of Medicine, Tokyo
Masashi Amano Department of Heart Failure and transplantation, National Cerebral and Cardiovascular Center, Suita
Yuya Matsue Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo
Yuko Fukuda Hyogo Cancer Center, Department of Onco-cardiology, Akashi
Hidekazu Tanaka Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe

English

Meet the Expert 5

March 10 (Sun), 2024 10:30-11:30 Room 10 Kobe International Exhibition Hall No.1 Building 2F Exhibition Hall B

ME5
State-of-the-Art Evolving understanding of residual cardiovascular risk
Chairpersons: Yuichi Oike Department of Molecular Genetics, Graduate School of Medical Sciences, Kumamoto University, Kumamoto
Yoshiaki Taniyama Department of Advanced Molecular Medicine, Graduate School of Medicine, Faculty of Medicine, Osaka University, Suita city
Speaker: Jun Morinaga Kyoto University, Kyoto
Ryuji Toh Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe
Philip S.Tsao VA Palo Alto Health Care System, Palo Alto, CA/ Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA

English

Meet the Expert 6

March 10 (Sun), 2024 13:20-14:50 Room 4 Kobe Portopia Hotel South Building 1F Ohwada C

ME6
All about vulnerable plaque
Chairpersons: Hiromasa Otake Division of Cardiovascular Medicine, Department of Internal Medicine,Kobe University Graduate School of Medicine , Kobe
Yasuhiro Honda Stanford University School of Medicine, USA
Speaker: Yasuhiro Honda Stanford University School of Medicine, USA
Fumiyuki Otsuka Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita
Takashi Kubo Tokyo Medical University, Hachioji Medical Center, Tokyo
Bon-Kwon Koo Seoul National University, Korea

Hot Topic

Japanese

Hot Topic 1

March 8 (Fri), 2024 08:00-08:30 Room 17 Kobe International Conference Center 3F International Conference Room

HT1
Chairpersons: Naoki Sato Kawaguchi Cardiovascular and Respiratory Hospital, Kawaguchi
Discussant:
Masaru Hatano Department of Cardiovascular Medicine, The University of Tokyo Hospital, Tokyo
Speaker: Keiichi Fukuda Heartseed Inc., Tokyo
Tatsuki Fujiwara Department of cardiovascular surgery, Tokyo Medical and Dental University, Tokyo
Yuki Ichihara Department of Cardiovascular Surgery, Tokyo Women's Medical University, Tokyo

Japanese

Hot Topic 2

March 8 (Fri), 2024 09:30-11:00 Room 6 Kobe Portopia Hotel South Building B1F Topaz

HT2
Current and Future Treatments in Patient with Mitral Valve Disease
Chairpersons: Yoshihiro Morino Division of Cardiology, Iwate Medical University, Yahaba
Taichi Sakaguchi Department of Cardiovascular Surgery, Hyogo Medical University, Nishinomiya
Speaker: Shunsuke Kubo Department of Cardiology, Kurashiki Central Hospital, Kurashiki
Mitsunobu Kitamura Department of Cardiology, Sakakibara Heart Institute, Tokyo
Taichi Sakaguchi Department of Cardiovascular Surgery, Hyogo Medical University, Nishinomiya

Japanese

Hot Topic 3

March 8 (Fri), 2024 13:30-15:00 Room 18 Kobe International Conference Center 3F Reception Hall

HT3
Revised Statement on MRI of Patients with CIEDs
Chairpersons: Takamichi Murakami Radiology, Kobe University Graduate School of Medicine, Kobe
Haruhiko Abe Department of Heart Rhythm Management, University Occupational and Environmental Health, Kitakyushu
Speaker: Shigeki Aoki Department of Radiology, Juntendo University, Tokyo
Toshiko Nakai Department of Medicine, Division of Advanced Therapeutics for Cardiac Arrhythmias, Nihon University School of Medicine, Tokyo
Atsuko Miyajima Devision of Medical Devices, National Institute of Health Sciences, Kawasaki
Ritsushi Kato Department of Cardiology, International Medical Center, Saitama Medical University, , Hidaka, Saitama
Kagayaki Kuroda Department of Human and Information Science, School of Information Science and Technology, Hiratsuka

English

Hot Topic 4

March 8 (Fri), 2024 16:25-17:25 Room 4 Kobe Portopia Hotel South Building 1F Ohwada C

HT4
Pulsed Field Ablation: Is this a Game Changer?
Chairpersons: Carlo de Asmundis Heart Rhythm Management Centre, Postgraduate Program in Cardiac Electrophysiology and Pacing, Universitair Ziekenhuis Brussel - Vrije Universiteit Brussel, European Reference Networks Guard-Heart, Brussels, Belgium
Hiroshi Nakagawa Department of Cardiovascular Medicine, Cleveland Clinic, USA
Speaker: Moritoshi Funasako Cardiology, Na Homolka Hospital, Czech Republic
Hiroshi Nakagawa Department of Cardiovascular Medicine, Cleveland Clinic, USA
Carlo de Asmundis Heart Rhythm Management Centre, Postgraduate Program in Cardiac Electrophysiology and Pacing, Universitair Ziekenhuis Brussel - Vrije Universiteit Brussel, European Reference Networks Guard-Heart, Brussels, Belgium

English

Hot Topic 5

March 9 (Sat), 2024 10:30-11:30 Room 4 Kobe Portopia Hotel South Building 1F Ohwada C

HT5
Novel Strategy for PAH Targeting BMPR2
Chairpersons: Marc Humbert University Paris-Saclay, France
Noriaki Emoto Clinical Pharmaceutical Science, Kobe Pharmaceutical University, Kobe
Speaker: Christophe Guignabert INSERM U999, Université Paris-sud, France
Hirofumi Sawada Department of Pediatrics, Mie University School of Medicine, Tsu
Takahiro Hiraide Department of Cardiology, Keio University School of Medicine, Tokyo

English

Hot Topic 6

March 9 (Sat), 2024 16:25-17:45 Room 6 Kobe Portopia Hotel South Building B1F Topaz

HT6
Coronary Physiology in 2024
Chairpersons: Hitoshi Matsuo Department of Cardiovascular Medicine, Gifu Heart Center, Gifu
Bon-Kwon Koo Seoul National University, Korea
Speaker: Chang-Wook Nam Keimyung University Dongsan Hospital, Korea
Carlos Collet Cardiovascular Center Aalst, OLV Clinic, Belgium
Hiromasa Ohtake Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe
Bon-Kwon Koo Seoul National University, Korea

Round Table Discussion

Japanese

Round Table Discussion 1

March 8 (Fri), 2024 13:30-15:00 Room 7 Kobe Portopia Hotel South Building B1F Emerald

RT1
How to establish an employment support system for patients with heart failure
Chairpersons: Taiki Higo Yumino Heart Clinic, Tokyo
Eriko Hisamatsu Department of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe
Speaker: Satoshi Yasuda Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai
Yasushi Oginosawa The Second Department of Internal Medicine, The University of Occupational and Environmental Health, Kitakyushu
Shunsuke Tatebe Department of Cardiovascular Medicine, Tohoku university hospital, Sendai
Yumiko Hori Department of Nursing, Department of Transplantation, National Cerebral Cardiovascular Center, Suita
Kazunori Takeuchi Sunset Rise Inc.

Japanese

Round Table Discussion 2

March 9 (Sat), 2024 08:00-09:30 Room 18 Kobe International Conference Center 3F Reception Hall

RT2
Pitfalls of management for MCS
Chairpersons: Tomoyuki Fujita Department of Cardiovascular Surgery, Tokyo Medical and Dental University, Tokyo Medical and Dental University
Takuma Sato Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo
Speaker: Togo Iwahana Department of Cardiology, Chiba University Hospital, Chiba
Naoki Tadokoro National Cerebral and Cardiovascular Center, Suita
Tatsuki Fujiwara Department of cardiovascular surgery, Tokyo Medical and Dental University, Tokyo
Takeo Fujino Advanced Cardiopulmonary Failure, Kyushu University, Fukuoka
Ryo Tanioka Department of Clinical Engineer, Kobe University Hospital, Kobe

Special Lecture

Japanese

Special Lecture 1

March 9 (Sat), 2024 16:25-16:55 Room 5 Kobe Portopia Hotel South Building B1F Sapphire

SL1
Revisiting the cardiac anatomy
Chairpersons: Tatsuya Nishii Department of Radiology, National Cerebral and Cardiovascular Center, Suita
Speaker: Shumpei Mori Cardiac Arrhythmia Center, UCLA , USA

English

Special Lecture 2

March 10 (Sun), 2024 10:30-11:00 Room 5 Kobe Portopia Hotel South Building B1F Sapphire

SL2
Study Series on Comparison Between Intravascular Imaging and Coronary Functional Test
Chairpersons: Kazuhiro Yamamoto Department of Cardiovascular Medicine and Endocrinology and Metabolism, Tottori University, Yonago
Speaker: Jian’an Wang Second Affiliated Hospital Zhejiang University School of Medicine/Dean of Second School of Clinical Medicine Zhejiang University, China

Morning Seminar

Japanese

Morning Seminar 1

March 9 (Sat), 2024 07:10-07:50 Room 17 Kobe International Conference Center 3F International Conference Room

MS1
EP University Presents: An ECG interpretation challenge!!
Koichi Nagashima Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo
Hidehira Fukaya Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara
Michifumi Tokuda Department of Cardiology, the Jikei University, Kastushika Medical Center, Tokyo
Riku Arai Department: Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo

Japanese

Morning Seminar 2

March 9 (Sat), 2024 07:10-07:50 Room 18 Kobe International Conference Center 3F Reception Hall

MS2
Lung ultrasound for heart failure management
Chairpersons: Hidekazu Tanaka Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe
Speaker: Junichi Imanishi Department of Cardiology, Hyogo Prefectural Awaji Medicine Center, Sumoto

Japanese

Morning Seminar 3

March 9 (Sat), 2024 07:10-07:50 Room 20 Kobe International Conference Center 5F 501

MS3
Physical examination for cardiovascular disease
Chairpersons: Kensuke Matsumoto Tamba medical Center, Tamba
Speaker: Takashi Muro Heart Valve Center, Midori Hospital, Kobe

Japanese

Morning Seminar 4

March 9 (Sat), 2024 07:10-07:50 Room 21 Kobe International Conference Center 5F 502

MS4
How to build up sustainable and resilient systems for heart failure team
Chairpersons: Eisaku Nakane Kitano hospital, Osaka
Speaker: Eisaku Nakane Kitano hospital, Osaka
Sayaka Hosoda Okazaki City Hospital, Aichi

Japanese

Morning Seminar 5

March 9 (Sat), 2024 07:10-07:50 Room 22 Kobe International Conference Center 5F 504+505

MS5
Management of Pregnancy with Cardiovascular Disease：Lesson from cases
Chairpersons: Chizuko Kamiya Department of Obstetrics and Gynecology , National Cerebral and Cardiovascular Center, Suita
Speaker: Nao Konagai Department of Obstetrics and Gynecology, National Cerebral and Cardiovascular Center, Suita

Japanese

Morning Seminar 6

March 10 (Sun), 2024 07:10-07:50 Room 17 Kobe International Conference Center 3F International Conference Room

MS6
Gather! Young doctors, learn practical antiarrhythmic drug usage from the expert!
Chairpersons: Ryudo Fujiwara Division of Cardiology, Osaka Saiseikai Nakatsu Hospital, Osaka
Atsushi Suzuki Department of Cardiology, Yodogawa Christian Hospital., Osaka
Case Presenter:
Wako Suehiro Department of Cardiovascular medicine, Yodogawa Christian Hospital, Osaka
Speaker: Akira Mashima Department of Cardiology, Osaka Saiseikai Nakatsu Hospital, Osaka
(Expert) Takanori Ikeda Department of Cardiovascular Medicine, Toho University Faculty of Medicine, Tokyo

Japanese

Morning Seminar 7

March 10 (Sun), 2024 07:10-07:50 Room 18 Kobe International Conference Center 3F Reception Hall

MS7
Hot Topics in VAD Management
Chairpersons: Osamu Seguchi Nagaya Internal Medicine, Osaka
Speaker: Shotaro Komeyama Transplant Medicine, National Cerebral and Cardiovascular Center, Suita
Tatsuki Fujiwara Department of cardiovascular surgery, Tokyo Medical and Dental University, Tokyo

Japanese

Morning Seminar 8

March 10 (Sun), 2024 07:10-07:50 Room 21 Kobe International Conference Center 5F 502

MS8
ACHD echo protocol from international society of adult congenital heart disease
Chairpersons: Terunobu Fukuda Kobe University, Kobe
Speaker: Naoto Kawamatsu Department of Cardiology, Faculty of Medicine, University of Tsukuba, Tsukuba
Norihisa Toh Department of Cardiology, Okayama University Hospital, Okayama

ACC-JCS Joint Symposium

English

Recent Evidence of the Social System for ST Elevated Myocardial Infarction

March 8 (Fri), 2024 13:30-15:00 Room 5 Kobe Portopia Hotel South Building B1F Sapphire

ACC-JCS
Chairpersons: Tetsuya Matoba Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka
Bryan Hadley Wilson Atrium Health/American College of Cardiology, USA
Speaker: Bryan Hadley Wilson Atrium Health/American College of Cardiology, USA
Tetsuya Matoba Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka
Athena Poppas Brown University, Lifespan, USA
Kiyotaka Hao Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai
Takeshi Yamamoto Division of Cardiovascular Intensive Care, Nippon Medical School Hospital, Tokyo

AHA-JCS Joint Symposium

English

Current Status and Challenges of iPS Cell Application to Cardiovascular Diseases

March 9 (Sat), 2024 8:00-9:30 Room 5 Kobe Portopia Hotel South Building B1F Sapphire

AHA-JCS
Chairpersons: Shinsuke Yuasa Department of Cardiology, Keio University School of Medicine
Joseph C. Wu Stanford University School of Medicine, USA
Speaker: Hesham Sadek University of Texas Southwestern, USA
Takeru Makiyama Department of Community Medicine Supporting System, Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto
Jianyi Zhang Biomedical Engineering, The University of Alabama at Birmingham, United States of America
Yuji Shiba Department of Regenerative Science and Medicine, Shinshu University, Matsumoto

KCS-JCS Joint Symposium

English

The Latest Trends in Aortic Stenosis Treatment

March 9 (Sat), 2024 10:30-12:00 Room 5 Kobe Portopia Hotel South Building B1F Sapphire

KCS-JCS
Chairpersons: Yoshihiro Seo Department of Cardiology, Nagoya City University Graduate School of Medical Sciences, Nagoya
Hyo-Soo Kim President of APSC, Seoul National University, Korea
Speaker: Seung-Hyuk Choi Sungkyunkwan University, Korea
Kentaro Hayashida Department of Cardiology, Keio University School of Medicine, Tokyo
Kiyuk Chang Catholic University, Korea
Masaki Izumo Department of Cardiology, St. Marianna University School of Medicine, Kawasaki

CSC-JCS Joint Symposium

English

New Devices for Interventional Cardiology

March 8 (Fri), 2024 16:25-17:55 Room 5 Kobe Portopia Hotel South Building B1F Sapphire

CSC-JCS
Chairpersons: Ken Kozuma Department of Cardiology, Teikyo University, Tokyo
Guangyuan Song Beijing Anzhen Hospital, China
Speaker: Ken Kozuma Department of Cardiology, Teikyo University, Tokyo
Guangyuan Song Beijing Anzhen Hospital, China
Atsunori Okamura Cardiovascular Center, Sakurabashi Watanabe Hospital, OSAKA
Wenzhi Pan Zhongshan Hospital, Fudan University, China
Kenichi Sakakura Jichi Medical University Saitama Medical Center, Saitama City

ESC-JCS Joint Symposium

English

Current Topics on Hypertrophic Cardiomyopathy and Secondary Cardiomyopathy

March 10 (Sun), 2024 8:00-9:30 Room 5 Kobe Portopia Hotel South Building B1F Sapphire

ESC-JCS
Chairpersons: Masaki Ieda Department of Cardiology, Keio University School of Medicine
Stephen Achenbach Friedrich Alexander University Erlangen Nuernberg, Germany
Speaker: Elena Arbelo Universitat de Barcelona, Spain
Toru Kubo Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University, Kochi
Gerhard Hindricks Charite University Hospital, Germany
Takeru Nabeta Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara

APSC-JCS Joint Symposium

English

Large-scale Clinical Research in Asia：Current Status and Future

March 8 (Fri), 2024 8:00-9:30 Room 5 Kobe Portopia Hotel South Building B1F Sapphire

APSC-JCS
Chairpersons: Satoshi Yasuda Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai
Issei Komuro Department of Frontier Cardiovascular Science, The University of Tokyo/International University of Health and Welfare, Tokyo
Speaker: Hyo-Soo Kim President of APSC, Seoul National University, Korea
Kotaro Nochioka Department of Cardiovascular Medicine, Tohoku University Hospital, Sendai
Khung Keong Yeo Cardiology, National Heart Centre Singapore, Singapore
Satoshi Honda Department of Cardiovascular medicine, National cerebral and cardiovascular center, Suita

WHF-JCS Joint Symposium

English

Why are We Failing on Secondary Prevention: New Approaches

March 9 (Sat), 2024 13:30-15:00 Room 5 Kobe Portopia Hotel South Building B1F Sapphire

WHF-JCS
Chairpersons: Junya Ako Department of Cardiovascular Medicine, Kitasato University, Sagamihara
Daniel Pineiro University of Buenos Aires, Argentina
Speaker: Daniel Pineiro University of Buenos Aires, Argentina
Tetsuya Takahashi Department of Physical Therapy, Faculty of Health Science, Juntendo University, Tokyo
Takashi Akasaka Nishinomiya Watanabe Cardiovascular Cerebral Center, Nishinomiya City
Yoshiyasu Minami Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara

Young Investigator’s Award (Clinical Research) Finalists Lectures

English

March 8 (Fri), 2024 13:30-15:30 Room 21 (Kobe International Conference Center 5F 502)

YIA-C
Chairpersons: Koichi Node Department of Cardiovascular Medicine, Saga University, Saga
Speaker: Yusuke Adachi Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo
Motoki Nakao Department of Cardiovascular Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo
Takashi Hiruma Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo
Mizuki Momoi Department of Cardiology, Keio University School of Medicine, Tokyo

Young Investigator’s Award (Basic Research) Finalists Lectures

English

March 8 (Fri), 2024 08:00-10:00 Room 21 (Kobe International Conference Center 5F 502)

YIA-B
Chairpersons: Toyoaki Murohara Department of Cardiology, Nagoya University, Nagoya
Speaker: Yohei Akiba Department of Cardiology, Keio University School of Medicine, Tokyo
Yuto Abe Department of Cardiology, Institute of Medicine, University of Tsukuba, Tsukuba
Jin Komuro Department of Cardiology, Keio University School of Medicine, Tokyo
Shunsuke Nishimura Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita
Yu Yamada Department of Cardiology, Institute of Medicine, University of Tsukuba, Tsukuba

Young Investigator's Award for International Student's Finalists Lectures

English

March 9 (Sat), 2024 08:00-10:00 Room 21 (Kobe International Conference Center 5F 502)

OSYIA
Chairpersons: Masaki Ieda Department of Cardiology, Keio University School of Medicine
Speaker: Adinata Aditya Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe
Jingbo Zhang Cardiovascular surgery, Osaka University Graduate School of Medicine, Osaka
Tuolisi Heryed Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo
Yuqing Xu Department of Cardiovascular Medicine, Kumamoto University, Kumamoto

International Young Investigator’s Award (Clinical Research Section) Finalists Lectures

English

March 9 (Sat), 2024 13:30-15:00 Room 21 (Kobe International Conference Center 5F 502)

IYIA-C
Chairpersons: Nozomi Watanabe Cardiovascular Physiology, University of Miyazaki Faculty of Medicine, Miyazaki
Speaker: Kanako Teramoto Biostatistics, National Cerebral and Cardiovascular Center, Osaka
Jin Hyuk Kim Korea University Guro Hospital, Korea
Mark Lachmann First Department of Medicine, Klinikum rechts der Isar, Technical University of Munich, Germany
Jun Akashi Second Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu
Vera Fortmeier Department of General and Interventional Cardiology, Heart and Diabetes Center North Rhine-Westphalia, Ruhr University Bochum, Bad Oeynhausen, Germany

International Young Investigator’s Award (Basic Research Section) Finalists Lectures

English

March 9 (Sat), 2024 10:30-11:30 Room 21 (Kobe International Conference Center 5F 502)

IYIA-B
Chairpersons: Koichiro Kuwahara Department of Cardiovascular Medicine, Shinshu University School of Medicine, Matsumoto
Speaker: Zheng-Wei Chen Cardiology, National Taiwan University Hospital Yunlin Branch, Taiwan
Tomohiro Hino Dpartment of Cardiovascular Medicine, Kyoto Prefectural University of Medicine, Kyoto
Chia-Hui Chen Graduate Institute and Department of Physiology, College of Medicine, National Taiwan University, Taiwan

Asian Pacific Grants for Innovative Research Plan Award（Clinical/Basic）

English

March 8 (Fri), 2024 16:25-17:25 Room 21 (Kobe International Conference Center 5F 502)

APA
Chairpersons: Tomoko Ishizu Department of Cardiology, University of Tsukuba, Tsukuba
Speaker: Jongmin Seo Mechanical Engineering, Kyung Hee University, Korea
Putrya Hawa Department of Pharmacology, Republic of Indonesia Defense University, Indonesia
Doan Pham Phuoc Long Cardiovascular Center, Hue University of Medicine and Pharmacy Hospital, Viet Nam
Wei-Hsin Chung China Medical University Hospital, Taichung, Taiwan, Taiwan

Japan Heart Foundation Satoh Memorial Award Lecture

English

Japan Heart Foundation Satoh Memorial Award Lecture

March 10 (Sun), 2024 15:30-16:30 Room 7 Kobe Portopia Hotel South Building B1F Emerald

SATO
Chairpersons: Hirata Ken-ichi Department of Internal Medicine, Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe
Speaker: Ito Kaoru Laboratory for Cardiovascular Genomics and Informatics, RIKEN Center for Integrated Medical Sciences, Yokohama

JCS Ethics Committee Session

English

Japanese

Lecture on Ethics

On-site March 10 (Sun), 2024 13:20-14:20 Room 1 Kobe Portopia Hotel 1F Portopia Hall

ETHIC
PPI in Cardiovascular Clinical Trials
Chairpersons: Shinichiro Ueda Department of Clinical Pharmacology & Therapeutics, University of the Ryukyus, Nishihara
Speaker: Isla Mackenzie Division of Molecular and Clinical Medicine, University of Dundee, UK

JCS International Committee Session

English

APSC President Session at JCS2024

March 9 (Sat), 2024 16:25-17:55 Room 15 Kobe International Exhibition Hall No.3 Building 1F Satellite Room

AES
Future Vision Conference by Young Doctors and Presidents from APSC and JCS: Current Status and Challenges of CVD in Asia

Flyer [PDF]

Special Lecture by International Honorary Members

English

March 9 (Sat), 2024 13:30-15:00 Room 2 Kobe Portopia Hotel South Building 1F Ohwada A

HM
Chairpersons: Issei Komuro Department of Frontier Cardiovascular Science, The University of Tokyo/International University of Health and Welfare, Tokyo
Wataru Shimizu Department of Cardiovascular Medicine, Nippon Medical School, Tokyo
Speaker: Kenneth Walsh Hemato Vascular Biology Center, Robert M. Berne Cardiovascular Research Center, University of Virginia School of Medicine, USA
Shih-Ann Chen Taichung and Taipei Veterans General Hospital, Taiwan

JIYC Original Session

English

March 9 (Sat), 2024 13:30-15:00 Room 15 Kobe International Exhibition Hall No.3 Building 1F Satellite Room

JIYC
Catheter Ablation of Atrial Fibrillation: Are We Targeting Atrial Myopathy or just AF?
Chairpersons: Satoshi Higuchi Department of Cardiology, Tokyo Women’s Medical University, Tokyo
Sung-Il Im Kosin University Gospel Hospital, Kosin University College of Medicine, Korea
Commentator:
Jong-Il Choi Korea University Anam hospital, Korea
Masaharu Masuda Kansai Rosai Hospital, Cardiovascular center, Amagasaki, Hyogo
Takanori Yamaguchi Department of Cardiovascular Medicine , Saga University , Saga
Katsuji Inoue Department of Cardiology, Pulmonology, Hypertension Nephrology, Ehime University Graduate School of Medicine, Toon
Speaker: Takanori Yamaguchi Department of Cardiovascular Medicine , Saga University , Saga
Satoshi Higuchi Department of Cardiology, Tokyo Women’s Medical University, Tokyo
Jong-Il Choi Korea University Anam hospital, Korea
Masaharu Masuda Kansai Rosai Hospital, Cardiovascular center, Amagasaki, Hyogo
Katsuji Inoue Department of Cardiology, Pulmonology, Hypertension Nephrology, Ehime University Graduate School of Medicine, Toon

Joint Session with AHA on Resuscitation Science

English

March 10 (Sun), 2024 10:30-12:00 Room 4 Kobe Portopia Hotel South Building 1F Ohwada

RSY
Current Status and Issues in In-hospital Cardiac Arrest and Rapid Response
Chairpersons: Dana Edelson University of Chicago Medicine, USA
Hiroyuki Okura Department of Cardiology, Gifu University Graduate School of Medicine
Speaker: Takaki Naito Department of Emergency and Critical Care Medicine, St. Marianna University School of Medicine, Kawasaki
Dana Edelson University of Chicago Medicine, USA
Satoshi Takeda The Jikei University School of Medicine, Emergency Department

JCS Guideline Committee Session

On Demand

English

QMR
Advancing the Implementation of Quality Indicators and Performance Measures: Strategies in the U.S. and Management Discussions on Arrhythmia
Chairpersons: Shun Kohsaka Department of Cardiology, Keio University School of Medicine, Tokyo
Kazuhiro Satomi Tokyo Medical University, Tokyo
Speaker: Alexander Sandhu Stanford University School of Medicine, USA
Jonathan Piccini Duke University School of Medicine, USA
Takeki Suzuki Department of Medicine, Indiana University, USA
Nobuhiro Ikemura University of Missouri-Kansas City/ Saint Luke's Mid America Heart Institute, USA
Keitaro Senoo Department of Cardiac Arrhythmia Research and Innovation , Kyoto Prefectural University of Medicine , Kyoto

JCS Editorial Committee Session

On Demand

English

CJ/EHJ Joint Session

CJEHJ
Chairpersons: Toshihisa Anzai Department of Cardiovascular Medicine, Hokkaido University Graduate School ot Medicine, Sapporo
Filippo Crea Department of Cardiovascular and Pneumological Sciences, Catholic University of the Sacred Heart, Italy
Speaker: Akihiro Nomura College of Transdisciplinary Sciences for Innovation, Kanazawa University, Kanazawa
Kazuomi Kario Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Shimotsuke
Vardas Panos University Hospital of Heraklion, Greece

On Demand

English

Circulation Journal Award Session

CJAS
Chairpersons: Toshihisa Anzai Department of Cardiovascular Medicine, Hokkaido University Graduate School ot Medicine, Sapporo
Speaker: Tomofumi Nakamura Department of Cardiology, Nagoya Heart Center, Nagoya
Hayato Tada Department of Cardiology, Kanazawa University Hospital, Kanazawa
Yosuke Higo Department of Cardiovascular Medicine, Shiga University of Medical Science, Shiga, Japan
Kensuke Takabayashi Department of Cardiology, Hirakata Kohsai Hospital, Hirakata
Yukiko Hata Department of Legal Medicine, Faculty of Medicine, University of Toyama, Toyama
Mari Amino Department of Cardiology, Tokai University, Isehara
Shao-Wei Chen Division of Thoracic and Cardiovascular Surgery, Department of Surgery, Chang Gung Memorial Hospital, Linkou Medical Center, Chang Gung University, Taiwan

JCS International Relations Committee Session

On Demand

English

Young ESC-JCS Collaboration Session

ESCCS
Chairpersons: Takatoshi Kasai Department of Cardiovascular Biology and Medicine, Juntendo University, Tokyo
Elizabeth Hill University of the West of England, UK
Speaker: Hady Atef Keele University, UK
Tomofumi Misaka Department of Cardiovascular Medicine, Fukushima Medical University, Fukushima
Ana Filipa Gomes Vogal Núcleo de Enfermagem em Cardiologia,
Shoichiro Yatsu Department of Cardiovascular Biology and Medicine, Juntendo University, Tokyo
c/o Congrès Inc.
3-6-13 Awajimachi, Chuo-ku, Osaka 541-0047, Japan
E-mail: jcs2024@congre.co.jp